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GENERAL INTRODUCTION 
The general aim of this dissertation is to test the hypothesis that adenosine may 
act as a negative feedback regulator for cardiopulmonary chemoreflex (CCR).  Powerful 
activation of the CCR results in severe hypotension which may lead to brainstem 
ischemia and cause release of adenosine into brainstem cardiovascular centers.  
Adenosine acting as a central neuromodulator may inhibit the reflex and prevent further 
deterioration of cardiovascular homeostasis observed following activation of the CCR. 
Adenosine - neuromodulator acting in life or death situations 
The role of adenosine as a neuromodulator in the central nervous system has 
been well established.  Adenosine operating via A1 or A2a receptors may inhibit or 
activate, respectively, central neurons and the release of neurotransmitters from nerve 
terminals.  Generally the inhibitory action of adenosine mediated via A1 receptors 
prevails in most of the central nervous system (16; 91).  For example, ingestion of 
caffeine, a nonselective antagonist of adenosine receptor subtypes, activates central 
processes by removing A1 receptor mediated inhibition which prevails over A2a receptor 
mediated facilitation.  However, in the nucleus of the solitary tract (NTS), where 
primarily integration of cardiovascular and other autonomic reflexes occur, the 
facilitatory A2a adenosine receptors play a dominant role over A1 receptor mediated 
inhibition.  This has been shown in classical studies by Barraco and Phillis who found 
that selective activation of NTS A2a adenosine receptors and nonselective activation of 
adenosine receptor subtypes in via microinjections of adenosine yield similar effects, i.e. 
decreases in mean arterial pressure (MAP) and heart rate (HR) (1; 8; 10; 80; 81; 122).  
In contrast, selective activation of adenosine A1 receptors located in the NTS evoked 
pressor responses, the effect opposite to that evoked by adenosine itself (1; 8; 10; 80; 
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81; 122).  Adenosine levels in the central nervous system, including the NTS, increase 
during critical, life threatening situations such as ischemia, hypoxia, and severe 
hemorrhage as well as during stress/hypothalamic defense response (30; 87; 110; 116-
118; 129; 138; 139).  In 
this setting adenosine 
levels are increased via 
two different mechanisms.  
Under pathological 
(hypoxic) conditions 
intracellular ATP is 
catabolized to adenosine 
in ischemic neurons and 
glial cells and adenosine is 
released into the 
extracellular space.  
Under physiological 
conditions, as for 
example, during hypothalamic  defense response ("flight or fight") ATP is neuronally 
released into the NTS and immediately catabolized to adenosine in the extracellular 
space by ectonucleotidases (118; 142).  ATP may be also released from glial cells 
stimulated by active central neurons in their proximity and it is rapidly degraded to 
adenosine by ectonucleotidases (45; 51).  Therefore, in all these pathological and 
physiological situations adenosine acts spatially, as a neuromodulator enveloping 
neural circuitry rather than acting as a neurotransmitter at specific synapses.  
Figure 1. Medullary pathways of the cardiopulmonary and arterial 
baroreceptors. Abbreviations: GABA,-amino-butyric acid; GLU, glutamate; 
NTS, nucleus of the solitary tract; CVLM, caudal ventrolateral medulla; 
IVLM, intermediate ventro lateral medulla RVLM, rostral ventrolateral 
medulla; AMB, nucleus ambiguus; IML, intermediolateral column of spinal 
cord; SG, sympathetic ganglion; IX, glossopharyngeal nerve; X, vagal nerve. 
Modified from Dampney RAL 1994 (32). 
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Adenosine is released during large homeostatic imbalance between demand and 
delivery of oxygen to the central neurons and may act as a neuromodulator correcting 
the imbalance.  Crucial reflexes responsible for cardio-respiratory homeostasis are 
primarily integrated in the NTS (Figure 1) (32).  Therefore, adenosine may play an 
important role in regaining homeostasis by modulation of these reflexes at the level of 
the NTS.  In support of this hypothesis, it has been reported that NTS contains the 
greatest density of adenosine uptake sites in the whole central nervous system (14). 
The Bezold Jarisch reflex 
The Bezold-Jarisch reflex, also known as the cardiopulmonary chemoreflex 
(CCR) is one of the homeostatic cardiovascular reflexes integrated in the NTS.  This 
reflex was initially discovered as a powerful depressor, and cardiac slowing reflex 
activated by veratrum alkaloids (3; 18; 34; 62).  Further studies showed that this reflex is 
evoked by activation of cardiopulmonary chemo-sensitive receptors and mechano-
sensitive stretch receptors located on sensory vagal C fibers within the left ventricle and 
atria in intimate proximity to the coronary vasculature and also within the pulmonary 
circulation (5; 18; 27; 50; 68; 85).  Chemo-sensitive and mechano-sensitive receptors 
are usually supplied by the same vagal afferent fibers and evoke similar reflex 
responses (100; 101).  Cardiopulmonary chemo-sensitive receptors are naturally 
activated via prostaglandins, radical oxygen species and serotonin released during 
cardiac ischemia, infarct and reperfusion (68; 97).  For example, serotonin is released 
from platelets, aggregating on damaged endothelium (83; 97) and increased serotonin 
levels activate 5HT3 serotonin receptors located on vagal cardiopulmonary afferent 
fibers (85; 136).  Serotonin is also released from endothelial cells of coronary arteries 
during hypoxia (17) and catabolism of ATP to ADP may also contribute to this process 
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(83).  The cardiopulmonary afferents may be also activated via other naturally released 
substances, for example, endogenous canabinoids operating via activation of vanilloid 
TRPV1 receptors, ATP operating via P2x receptors, nicotine, etc. (44; 67; 93).  The 
CCR opposes the sympathoactivatory reflexes mediated by bradykinin released in the 
ischemic heart (4; 66; 127).  This interaction between two opposite reflex effects may 
provide fine tuning of cardiovascular regulation during cardiac ischemia as suggested 
by Longhurst (66).  The CCR pathway is similar to that mediating the arterial baroreflex 
and involves glutamatergic activation of NTS neurons, glutamatergic projection from the 
NTS to the caudal ventrolateral medulla (CVLM) and GABA-ergic projection from CVLM 
to the rostral ventrolateral medulla (RVLM) (132).   
Activation of both mechano-sensitive and chemo-sensitive cardiopulmonary 
receptors evokes powerful reflex bradycardia, vasodilation and hypotension.  These 
reflex responses are cardio-protective as they decrease afterload and heart rate, 
reducing oxygen demand in the hypoxic heart, therefore improving left ventricular 
function (37; 92; 97).  This may help reduce heart muscle damage, prevent pulmonary 
edema, and restore cardiovascular balance despite existing coronary hypoperfusion 
(37).  However, powerful activation of this reflex under ischemic conditions will cause 
apnea, exaggerate the decreases in cardiac output and total peripheral resistance 
causing profound hypotension thereby decreasing perfusion of vital organs resulting in 
cardiogenic shock (34; 48). Several studies showed that this reflex may be responsible 
for infarct related bradyarrhythmias, severe hypotension and sudden cardiac death 
especially in patients with infarct of the inferior and posterior wall of the heart (23; 68; 
135).  This reflex may also be responsible for vasovagal syncope, i.e. transient cerebral 
ischemia as a result of marked reflex hypotension (68).  Sudden cardiac death in young 
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athletes is also often attributable to the Bezold-Jarisch reflex (13; 94).  Summarizing, 
the cardiopulmonary chemoreflex (CCR) may help restore hemodynamic balance during 
myocardial ischemia, or it can further exaggerate the imbalance leading to cerebral 
ischemia and death.  The final outcome may turn positive or negative depending on the 
fine tuning of this powerful reflex mechanism within the central nervous system.   When 
powerful activation of the CCR leads to severe hypotension and brainstem ischemia 
adenosine may be released into the NTS and act as a neuromodulator restricting the 
reflex and preventing further deterioration of homeostatic imbalance and its deadly 
consequences.   
Adenosine neuromodulation of cardiovascular control at the level of the NTS 
Although adenosine acts spatially during severe hemodynamic imbalance 
leading to brainstem ischemia (87; 110; 129; 138; 139) it may create specific patterns of 
autonomic responses due to differential location of inhibitory A1 and facilitatory A2a 
receptors on NTS neurons integrating specific cardiovascular reflexes and projecting 
finally to specific regional sympathetic outputs (103; 108).  Selective stimulation of these 
antagonistic receptor subtypes in the NTS results often, but not always, in reciprocal 
sympathetic and hemodynamic responses.  Previous studies from our laboratory 
showed that selective stimulation of NTS adenosine A1 receptors evokes mostly (2/3) 
pressor responses and differential regional sympathoactivation: preganglionic adrenal 
(pre-ASNA) > renal (RSNA)  lumbar (LSNA) sympathetic nerve activity (107).  These 
responses were mediated via inhibition glutamatergic transmission in the arterial 
baroreflex pathway as bilateral sinoaortic denervation + vagotomy as well as blockade 
of ionotropic glutamatergic transmission in the NTS abolished the pressor and 
sympathoactivatory responses (107).  Relatively high variability of pressor/depressor 
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and vasoconstrictor/vasodilator responses evoked by stimulation of NTS A1 adenosine 
receptors is a result of simultaneous triggering of 3 vasoactive responses: 1) 
sympathetic vasoconstriction; 2) preferential activation of the adrenal medulla, release 
of epinephrine into the circulation and -adrenergic vasodilation; 3) release of 
vasopressin into the circulation due to inhibition of baroreflex pathway which normally 
restricts release of this peptide from hypothalamic nuclei (paraventricular and 
supraoptic) (32; 71-73).  Direct assessment of the effect of NTS A1 receptors on 
baroreflex control of HR and regional sympathetic outputs confirmed implications from 
previous studies that in fact A1 adenosine receptors inhibit arterial baroreflex 
mechanisms at the level of the NTS (73; 107).  This study showed that stimulation of 
NTS A1 adenosine receptors uniformly shifted all baroreflex stimulus response function 
curves (for HR, RSNA, pre-ASNA and LSNA) over 50 mmHg toward higher MAP (102).  
Following the stimulation greater baroreceptor activation was required to overcome A1 
adenosine receptor-mediated inhibition of neurotransmission in the baroreflex pathway 
to evoke baroreflex responses.  The baroreflex functions were shifted rightward along 
the MAP axis with only minor, regionally specific alterations of the range and gain of 
arterial baroreflex control.  This was consistent with inhibition of neurotransmitter 
release from baroreceptor afferents terminating in the NTS. 
Activation of NTS A2a adenosine receptors, which functionally prevail over A1 
receptors in the NTS, evokes more contrasting regional sympathetic and vascular 
responses that those evoked by NTS A1 receptor stimulation.  Following selective 
stimulation of A2a adenosine receptors marked decreases in MAP, HR and RSNA are 
accompanied with substantial increases in pre-ASNA, whereas no significant changes 
in LSNA were observed (104; 105).  Note that NTS A2a and A1 receptors reciprocally 
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affect MAP and RSNA, have different effects on LSNA; however they both preferentially 
activate the adrenal medulla innervated by pre-ASNA.  These two receptor subtypes 
have also reciprocal effects on regional vasculature: A1 receptors evoke mostly 
vasoconstriction (sympathetic and vasopressinergic) (72), whereas A2a receptors elicit 
differential regional vasodilation (iliac>>mesenteric>renal) which is mediated mainly by 
activation of the adrenal medulla and -adrenergic vasodilation (9; 59).  Although NTS 
A2a adenosine receptors have highly diverse effects on regional sympathetic outputs 
and vascular beds, these receptors do not directly affect baroreflex mechanisms 
controlling the sympathetic outputs.  The recent study from our laboratory showed that 
NTS A2a receptors do not reset regional sympathetic baroreflex function curves along 
the MAP axis, therefore they do not alter the reflex reactivity to activation of arterial 
baroreceptors by changes in MAP (54). NTS A2a adenosine receptor-mediated 
reciprocal shifts in baseline level of regional sympathetic activity (decreases in RSNA 
and increases in pre-ASNA) reciprocally altered the range and the gain of baroreflex 
control of RSNA (decreases) vs. pre-ASNA (increases).  However the baseline shifts 
and consequent alterations of range and gain of baroreflex control of these sympathetic 
outputs were mediated via non-baroreflex mechanisms as the stimulus-response 
baroreflex functions were not shifted along the MAP axis. 
Interestingly, adenosine operating in the NTS via A2a receptors (which 
functionally prevail over A1 receptors) was initially considered as a neuromodulator 
which facilitates glutamatergic neurotransmission in the arterial baroreflex pathway 
because "baroreflex like" global hemodynamic effects (decreases in MAP and HR) were 
observed following microinjections into the NTS of adenosine as well as of the selective 
agonist of A2a adenosine receptors (CGS 21680) (1; 8; 10; 80; 81; 122).  However, more 
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precise analysis of regional sympathetic responses evoked by selective stimulation of 
NTS A2a adenosine receptors in our laboratory showed that this concept was very 
unlikely.  Although MAP, HR and RSNA decreased upon stimulation of NTS A2a 
receptors, which was consistent with facilitation of NTS baroreflex mechanisms, LSNA 
did not change and pre-ASNA increased in this setting, which was just opposite to 
decreases in pre-ASNA response evoked by activation of the arterial baroreflex (99; 
104; 105).  In addition, bilateral sinoaortic denervation + vagotomy or bilateral inhibition 
of glutamatergic transmission in the NTS did not significantly alter the hemodynamic 
and regional neural responses to stimulation of NTS A2a receptors (105; 106).  Finally, 
the direct assessment of baroreflex stimulus-response function curves confirmed that 
NTS A2a adenosine receptors do not reset arterial baroreflex reactivity (54).  Taken 
together these data indicate that activation of NTS A2a receptors markedly alters 
baseline levels of regional sympathetic nerve activity and blood flow in regional vascular 
beds via non-baroreflex mechanisms as these cardiovascular responses are observed 
after deafferentation of the NTS.  Therefore, it is likely that A2a receptors may modulate 
activity of nerve fibers descending to the NTS from higher structures, most likely from 
the hypothalamus which have dense, reciprocal connection with the NTS (32; 64; 96). 
A2a receptor-mediated modulation of this descending activity may interact with specific 
cardiovascular reflexes integrated in the NTS and finally evoke the diverse regional 
cardiovascular and neural responses. 
Hypothetical adenosine neuromodulation of the CCR 
As it was hypothesized above, adenosine may be released into the NTS during 
powerful reflex decreases in MAP evoked by activation of the CCR and inhibit this reflex 
preventing potential deadly consequences (fainting or even sudden death).  This 
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hypothesis is consistent with inhibitory action of adenosine via A1 receptors.  Since both 
the CCR and arterial baroreflex pathways are mediated via the same medullary 
structures (NTS, CVLM and RVLM) and neurotransmitters (32; 131) and selective 
stimulation of NTS A1 adenosine receptors does inhibit the arterial baroreflex pathway, it 
is likely that also the CCR pathway may be inhibited by this adenosine receptor 
subtype.  However, the potential effect of NTS A2a adenosine receptors, which are much 
more functionally relevant in the NTS than their A1 counterparts, is not so clear.   
Although activation of NTS A2a receptors evoked marked, contrasting regional 
sympathetic and hemodynamic responses these receptors did not inhibit the arterial 
baroreflex pathway at the level of the NTS (54; 104; 105).  Interestingly, the pattern of 
regional sympathetic responses evoked by selective stimulation of NTS A2a receptors 
resemble the pattern occasionally reported following stimulation of the CCR, i.e. 
decreases in RSNA, increases in pre-ASNA and no changes in LSNA (40; 52; 130), 
although other studies from our laboratory and by others reported uniform CCR-
mediated inhibition of regional sympathetic outputs (19; 38; 57; 95; 100).  The 
similarities between patterns of regional sympathetic responses triggered by the CCR 
and stimulation of NTS A2a receptors could suggest that A2a receptors may facilitate the 
CCR under some rare circumstances.  This would be against our hypothesis, that 
adenosine serves as a negative feedback regulator for the CCR via both A1 and A2a 
receptors located in the NTS.  However, our preliminary data showed that both A1 and 
A2a receptors may inhibit the regional sympathetic and hemodynamic responses evoked 
by stimulation of the CCR (78), which supports our hypothesis that adenosine indeed 
inhibits the CCR via both A1 and A2a receptor subtypes which mediate the inhibition via 
different mechanisms: A1 receptors may directly inhibit glutamatergic transmission in 
10 
 
CCR pathway whereas A2a receptors may facilitate release of an inhibitory 
neurotransmitter which in turn may inhibit the CCR pathway at the level of the NTS.  
Since stimulation of NTS A2a receptors evokes decreases in RSNA, increases in pre-
ASNA and no changes in LSNA it was reasonable to speculate that the A2a receptor 
mediated inhibition of the CCR responses will be regionally specific: it may be greater 
for pre-ASNA as the effect of A2a receptor stimulation is opposite to that evoked by the 
CCR and the smallest for RSNA as both NTS A2a receptors and activation of the CCR 
inhibit this sympathetic output. The A2a receptor-mediated inhibition of LSNA responses 
to stimulation of the CCR may be at intermediate level between those for pre-ASNA and 
RSNA.   
Among possible inhibitory mechanisms which can be triggered in the NTS to 
inhibit the CCR pathway the most plausible choice is GABA released from intrinsic NTS 
GABA-ergic neurons or nerve terminals.  Although there are no data which confirm the 
presence of GABA-ergic negative feedback in the CCR pathway at the level of the NTS, 
this GABA-ergic negative feedback is well documented in arterial baro- and chemoreflex 
pathways (55; 56; 65; 74; 119-121; 133; 140; 141). In addition, a recent review article by 
Zhang and Mifflin postulates that the negative GABA-ergic feedback is probably present 
in all cardiovascular reflexes integrated in the NTS (141).   
It still remains undocumented if adenosine A1 and A2a adenosine receptors are 
present in the CCR pathway.  It is likely that NTS A1 receptors inhibit the CCR pathway 
similarly as they inhibit the arterial baroreflex pathway (102).  However, the presence of 
A2a receptors in the CCR pathways is not so certain as these receptors did not inhibit or 
facilitate arterial baroreflex control of the regional sympathetic outputs. 
The studies performed in frame of this dissertation answered all the above 
11 
 
questions and positively proved the main hypothesis that adenosine operating via both 
A1 and A2a receptors in the NTS network serves as a negative feedback regulator for 
CCR control of regional sympathetic outputs and hemodynamic variables. 
Experimental plan 
Adenosine differentially modulates arterial baroreflex control of regional 
sympathetic outputs via A1 and A2a receptors located in the NTS circuitry.  Based on 
previous studies and preliminary data I hypothesize that antagonistic A1 and A2a 
adenosine receptors may act in concert although via different mechanisms to inhibit the 
CCR.  Adenosine is released into the NTS during hypoxia and severe post-hemorrhagic 
hypotension; it may be also released during profound reflex hypotension which occurs 
during powerful activation of the CCR.  Therefore adenosine operating via both A1 and 
A2a receptors may serve as a negative feedback regulator for CCR mechanisms at the 
level of the NTS. 
In addition, controversies in literature exist on regional sympathetic responses to 
activation of the CCR.  Therefore, before addressing modulatory effect of adenosine 
receptor subtypes on CCR control of regional sympathetic outputs the differential 
regional reflex effects will be assessed using simultaneous recordings from three 
sympathetic nerves (renal, adrenal and lumbar). 
Specific aims of dissertation 
1. To test hypothesis that activation of A1 adenosine receptors in the NTS 
differentially inhibits hemodynamic and regional sympathetic responses evoked 
by activation of the CCR. 
2. To test hypothesis that activation of NTS A2a receptors (acting in concert with A1 
receptors) differentially inhibits the CCR control of regional sympathetic outputs. 
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3. To test hypothesis that activation of NTS A2a adenosine receptors mediates 
inhibition of hemodynamic and regional neural sympathetic responses evoked by 
activation of the CCR via facilitating of GABA release from NTS GABA-ergic 
neurons/terminals.    
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CHAPTER 1 
Activation of NTS A1 adenosine receptors inhibits regional sympathetic 
responses evoked by activation of cardiopulmonary chemoreflex 
ABSTRACT 
Previously we have shown that, adenosine operating via the A1 receptor subtype 
may inhibit glutamatergic transmission in the baroreflex arc within the NTS and 
differentially increase renal (RSNA), preganglionic adrenal (pre-ASNA) and lumbar 
(LSNA) sympathetic nerve activity (ASNA>RSNA≥LSNA).  Since the cardiopulmonary 
chemoreflex and the arterial baroreflex are mediated via similar medullary pathways 
and glutamate is a primary transmitter in both pathways, it is likely that adenosine 
operating via A1 receptors in the NTS may differentially inhibit regional sympathetic 
responses evoked by activation of cardiopulmonary chemoreceptors.  Therefore, in 
urethane/chloralose anesthetized rats (n=37) we compared regional sympathoinhibition 
evoked by the cardiopulmonary chemoreflex (activated with right atrial injections of 
serotonin 5HT3 receptor agonist, phenylbiguanide, PBG,1-8 g/kg) before and after 
selective stimulation of NTS A1 adenosine receptors (microinjections of N
6-cyclopentyl 
adenosine, CPA, 0.033-330 pmol/50 nl).  Activation of cardiopulmonary chemoreceptors 
evoked differential, dose dependent sympathoinhibition (RSNA>ASNA>LSNA) and 
decreases in arterial pressure and heart rate.  These differential sympathetic responses 
were uniformly attenuated in a dose dependent manner by microinjections of CPA into 
the NTS.  Volume control (n=11) and blockade of adenosine receptor subtypes in the 
NTS via 8-(p-sulfophenyl) theophylline (8-SPT; 1 nmol in 100 nl) (n=9) did not affect the 
reflex responses.  We conclude that activation of NTS A1 adenosine receptors uniformly 
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inhibits neural and cardiovascular cardiopulmonary chemoreflex responses.  A1, 
adenosine receptors have no tonic modulatory effect on this reflex under normal 
conditions.  However, when adenosine is released into the NTS (i.e. during stress or 
severe hypotension/ischemia) it may serve as negative feedback regulator for 
depressor and sympathoinhibitory reflexes integrated in the NTS. 
INTRODUCTION 
Numerous studies have shown that adenosine operates as a central 
neuromodulator of cardiovascular control at the level of the NTS (1; 9; 54; 59; 72; 81; 
105; 107; 108; 110; 116).  In the central nervous system adenosine serves as an 
inhibiting or stimulating neuromodulator operating via A1 and A2a receptors, respectively 
(90).  The primary natural source of adenosine is ATP released from nerve terminals 
and glial cells which is subsequently catabolized to adenosine by ectonucleotidases (90; 
114; 142).  Importantly, adenosine is also released into the extracellular space during 
life threatening homeostatic imbalances such as hypoxia, ischemia and severe 
hemorrhage; in these pathological situations adenosine results from massive catabolism 
of intracellular ATP (87; 110; 129; 138; 139).  Inasmuch as, the most basic, life 
supporting, reflexes (cardiovascular, respiratory and other autonomic reflexes) are 
primarily integrated in the NTS (32), it is not surprising that the greatest density of 
adenosine uptake sites in the entire central nervous system is located in the NTS (14).   
The Bezold-Jarisch reflex (also termed the cardiopulmonary chemoreflex) was 
initially discovered as a powerful depressor and cardiac slowing response to veratridine 
alkaloids (62). It is mediated by polymodal receptors located on myelinated and 
unmyelinated vagal afferents from the cardiopulmonary region which are activated 
physiologically via mechanical and/or chemical stimuli as shown in extensive studies 
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performed on dogs and cats by Colleridges, Paintal, Dawes and Thoren  (26; 27; 34; 84; 
85; 126).  In the rat the equivalent fibers are unmyelinated afferents which only exhibit 
low or high activation thresholds (124; 125).  The majority of cardiac vagal afferents 
activated by mechanical stimuli in the rat are also activated by the serotonin 5HT3 
receptor agonist, phenylbiguanide (PBG)(100; 101).  The cardiopulmonary chemoreflex 
may be naturally activated via serotonin released from aggregated platelets during 
coronary clot formation or from ischemic endothelial cells (17; 43; 83) as well as via 
other naturally released substances, for example, endogenous canabinoids operating 
via activation of vanilloid TRPV1 receptors, ATP operating via P2x receptors, nicotine, 
etc. (44; 67; 93).  Consistently, the cardiopulmonary chemoreflex is markedly enhanced 
during the acute phase of myocardial infarction (67; 93) which may be cardio-protective 
as it causes decreases in HR and afterload leading to decreased oxygen demand of the 
ischemic heart (37; 68; 97).  However, powerful activation of this reflex may lead to 
severe hypotension, cerebral ischemia, bradyarrhythmia and even sudden cardiac 
death (13; 48; 68).  If the reflex hypotension exceeds the capabilities of brainstem 
vascular autoregulation, adenosine may be released into the NTS from ischemic central 
neurons and glial cells.  This increase in adenosine can have wide ranging, complex 
actions on the central integration of cardiovascular reflexes in these settings. 
Adenosine operating via A1 receptor subtype in the NTS may inhibit 
glutamatergic transmission in the baroreflex arc, reset arterial baroreflex control of heart 
rate (HR) and regional sympathetic nerve activity toward higher mean arterial pressure 
(MAP) and differentially affect baroreflex functions for renal (RSNA), preganglionic 
adrenal (pre-ASNA), postganglionic adrenal (post-ASNA) and lumbar (LSNA) 
sympathetic outputs (102; 107).  Since the cardiopulmonary chemoreflex and arterial 
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baroreflex are mediated via similar medullary pathways and glutamate is a primary 
transmitter in both pathways at the level of the NTS (131), it is likely that adenosine 
operating via NTS A1 receptors may differentially inhibit regional sympathetic and 
hemodynamic responses evoked by activation of cardiopulmonary chemoreceptors.  
This mechanism may serve as a negative feedback regulator for the cardiopulmonary 
chemoreflex, preventing the potentially deadly effects of over-excitation of the reflex 
which could result in life threatening hypotension and bradyarrhythmia.  However, it 
remains unknown if A1 adenosine receptors are present on those NTS neurons which 
mediate the cardiopulmonary chemoreflex.  Our previous studies suggested differential 
localization of A1 adenosine receptors on NTS neurons targeting different sympathetic 
outputs (103; 107).  However, it remains unknown if these receptors are differentially 
located on those NTS neurons which mediate cardiopulmonary chemoreflex control of 
regional sympathetic outputs.  Specifically, it is unknown if activation of NTS A1 
adenosine receptors differentially attenuates the inhibition of the pre-ASNA vs. RSNA 
vs. LSNA evoked by activation of cardiopulmonary chemoreceptors.  The present study 
was designed to address the above hypotheses. 
In addition, there are controversial reports on the responses of regional 
sympathetic outputs evoked by stimulation of cardiopulmonary afferents (19; 38; 40; 52; 
57; 95; 100; 101; 130). For example, in some studies stimulation of cardiopulmonary 
5HT3 receptors resulted in reflex increases in pre-ASNA, no change in LSNA and 
decreases in RSNA (40; 52; 130) whereas other studies showed uniform inhibition of 
these regional sympathetic outputs in this setting (19; 38; 95; 100). These discrepancies 
may result from comparisons of single nerve recordings performed in different animals 
under different experimental conditions in different laboratories. In the present study the 
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attempt was made to simultaneously record the reflex responses from all these 
sympathetic outputs (renal, adrenal and lumbar) in the same animal to allow quantifying 
and comparing the regionally specific differences in the reflex reactivity under identical 
experimental conditions. 
METHODS 
All protocols and surgical procedures employed in this study were reviewed and 
approved by the Institutional Animal Care and Use Committee and were performed in 
accordance with the Guide for the Care and Use of Laboratory Animals endorsed by the 
American Physiological Society and published by the National  Institutes of Health.  
Design 
Regional sympathetic (RSNA, pre-ASNA, post-ASNA and LSNA) and 
hemodynamic (MAP and HR) responses evoked by graded stimulation of 
cardiopulmonary chemoreceptors via injections into the right atrium of increasing doses 
of 5HT3 serotonin receptor agonist, PBG (1, 2, 4, and 8 g/kg) were studied
 in 57 male 
Sprague-Dawley rats (380.0 ± 6.0 g).  In 37 rats, A1 adenosine receptors were
 activated 
in the caudal NTS via bilateral microinjections of three different doses of the selective A1 
receptor agonist, N6-cyclopentyl adenosine, (CPA, 0.033, 3.0, and 330 pmol in 50 nl; 
numbers of animals in each group were 10, 13, and 14, respectively).  In 9 rats, 
adenosine receptors were inhibited with water soluble, nonselective A1 and A2a receptor 
antagonist 8-(p-sulfophenyl) theophylline (8-SPT, 1 nmol in 100 nl).  In 11 rats, the effect 
of bilateral microinjections of vehicle (artificial cerebrospinal fluid, ACF, 50 nl) on 
cardiopulmonary chemoreflex reactivity was evaluated.  The cardiopulmonary 
chemoreflex stimulus-response curves obtained under control conditions were 
compared with the curves obtained approximately 5 min after bilateral stimulation or 
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inhibition of NTS A1 adenosine receptors or following volume control. The 
cardiopulmonary chemoreflex reactivity was also assessed approximately one hour 
after the microinjections of A1 adenosine receptor agonist into the NTS (recovery). The 
timeline of the protocols is presented in Figure 2.   
  
Instrumentation and measurements 
All procedures were described in detail previously (9; 54; 99; 100; 102; 105-107; 
109-111).  Briefly, male Sprague-Dawley rats (Charles River) were anesthetized with a 
mixture of α-chloralose (80 mg·kg-1) and urethane (500 mg·kg-1 i.p.), tracheotomized, 
connected to a small-animal respirator (SAR-830, CWE, Ardmore, PA), and artificially 
ventilated with 40% oxygen, 60% nitrogen mixture.  Arterial blood gases were tested 
occasionally (Radiometer, ABL500, OSM3), and ventilation was adjusted to maintain 
Po2, Pco2, and pH within normal ranges.  Average values measured at the end of each 
experiment were: Po2 = 166.1 ± 5.1 Torr, Pco2 = 35.3 ± 1.4 Torr and pH = 7.43 ± 0.01.  
The left femoral artery and vein were catheterized to monitor arterial blood pressure and 
infuse drugs and supplementary doses of anesthesia (12–21 mg·kg-1·h-1 of α-chloralose 
and 76–133 mg·kg-1·h-1 of urethane dissolved in 2.4–4.2 ml·kg-1·h-1 saline), respectively.  
8- SPT 1 nmol/100 nl
~ 60 min
PBG (g/kg)
CONTROL EXPERIMENTAL RECOVERY
PBG (g/kg) PBG (g/kg)
1
4
2
8              
1
4
2
8              
~ 30 min ~ 5 min           
1
4
2
8              
ACF 50nl
CPA 0.033 - 330 pmol/ 50 nl
Figure 2. Timeline of experiments. Small arrows indicate injections of phenylbiguanide into the right atrium (1-8 
g/kg). Double large arrows indicate bilateral microinjections into the NTS of: A1 adenosine receptor agonist CPA 
(0.033, 3.3 and 330 pmol in 50 nl), non-selective adenosine receptor antagonist, 8-SPT (1 nmol in 100 nl) or 
volume control (microinjections into the NTS of artificial cerebrospinal fluid, ACF, 50 nl).  
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An additional catheter was inserted into the right atrium via right jugular vein for intra-
atrial PBG injections. 
Sinoaortic denervation was performed and tested similarly as it was described in 
previous papers from our laboratory (100; 105; 107).  This procedure was performed to 
minimize baroreflex compensation for the decreases in MAP evoked by stimulation of 
cardiopulmonary receptors and also to eliminate possible activation of arterial 
chemoreceptors by PBG (15; 58).  Importantly, unloading of arterial baroreceptors may 
differentially increase the regional sympathetic nerve activity thus it may obscure the 
regional differences in cardiopulmonary chemoreflex reactivity (99).  Special attention 
was paid to preserve the integrity of the vagus nerve during stripping of the bifurcation 
of common carotid artery and cutting aortic depressor, superior laryngeal and 
sympathetic nerves.  Experiments in which stimulation of the cardiopulmonary receptors 
with the maximal used dose of PBG (8g/kg) evoked less than 20% decrease in MAP 
were not analyzed. 
Neural recordings 
In each experiment, simultaneous recordings from three (n=26) or two 
sympathetic outputs (n=31) were performed.  Renal and adrenal nerves were exposed 
retroperitoneally form a flank incision, whereas lumbar sympathetic trunk was exposed 
from midabdominal incision.  Neural recordings were accomplished as described 
previously (54; 99; 100; 102; 105-107; 109-111).  Neural signals were initially amplified 
(2,000–20,000×) with bandwidth set at 100–1,000 Hz, digitized, rectified, and averaged 
in 1-s intervals.  Background noise was determined 30–60 min after the animal was 
euthanized, yet still artificially ventilated to leave unaltered any potential movement 
artifacts.  Determination of noise in pre-ASNA requires long post mortem recording as 
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this nerve may be active up to an hour after the euthanasia (21; 22).  Resting nerve 
activity before each stimulation of the cardiopulmonary receptors was normalized to 100%. 
The ratio between preganglionic and total nerve activity was initially tested with 
an intravenous bolus injection of the short-lasting (1-2 min) ganglionic blocker, Arfonad 
(trimethaphan, 2 mg·kg-1; Hoffmann-La Roche) and finally evaluated at the end of each 
experiment with hexamethonium (20 mg·kg-1 i.v.).  RSNA was almost completely 
postganglionic; 3.8 ± 0.7 % (n = 56) of the activity persisted after the ganglionic 
blockade.  LSNA was predominantly postganglionic; 33.1 ± 3.9 % (n = 40) of 
preganglionic activity remained after the blockade.  According to the criteria established 
in our previous studies (54; 99; 102; 105-107; 109-111), pre-ASNA was considered as 
predominantly preganglionic if the activity remaining after ganglionic blockade at the 
end of each experiment was >75 % or predominantly postganglionic if the remaining 
activity after the blockade was <50%.  For total of 47 adrenal nerve recordings 37 were 
found predominantly preganglionic, 4 predominantly postganglionic, and 6 had 
intermediate composition (int-ASNA) where 50-75% of activity remained after the 
blockade.  Average activity measured after ganglionic blockade was 107.2 ± 3.3 %, 
32.7±5.6 % and 65.0±2.2 % for pre-ASNA, post-ASNA and int-ASNA, respectively.  Pre-
ASNA increased over 100 % likely because of unloading of intact cardiopulmonary and 
the remaining peripheral baroreceptors during the decrease in MAP after the ganglionic 
blockade.  The ganglionic blockade produces usually larger increases in pre-ASNA (17-
28%) in rats with intact arterial baroreceptors (54; 102; 105).  The arterial pressure and 
neural signals were digitized and recorded with a Hemodynamic and Neural Data 
Analyzer (Biotech Products, Greenwood, IN), averaged over 1-s intervals, and stored on 
hard disk for subsequent analysis. 
21 
 
Microinjections into the NTS 
Bilateral microinjections of three different doses of the selective A1 receptor 
agonist, CPA (0.033, 3.3 and 330 pmol in 50 nl of ACF) and the nonselective A1-A2a 
receptor antagonist, 8-SPT (1nmol in 100nl of ACF) were made with multibarrel glass 
micropipettes into the medial region of the caudal NTS as described previously (9; 54; 
102; 105-107; 109-111).  The doses and volumes of the agonist and antagonist were 
the same as used in our 
previous studies (54; 102; 
106; 107; 109-111).  The 
drugs were dissolved in ACF, 
and the pH was adjusted to 
7.2 to unify pH across all our 
studies; in previous studies 
we used acidic A2a 
adenosine receptor agonist 
(CGS 21680) which often 
precipitated in pH >7.2.  In a 
separate group of animals 
bilateral microinjections of 
vehicle (50 nl of ACF at pH = 
7.2) into the same site of the 
NTS were performed as a volume control.  All microinjection sites were marked with DiI 
lypophilic dye (Molecular Probes, CA) and verified histologically as described previously 
(9; 54; 102; 105-107; 109-111).  The microinjection sites are presented in Figure 3 using 
Figure 3. Microinjection sites in subpostremal NTS for all CPA 
experimental groups. Schematic diagrams show transverse sections of 
the medulla oblongata from a rat brain. AP, area postrema; c, central 
canal; 10, dorsal motor nucleus of vagus nerve; 12, nucleus of 
hypoglossal nerve; Ts, tractus solitarius; Gr, gracile nucleus; Cu, 
cuneate nucleus. Scale is shown at bottom; number on left schematic 
diagram denotes the rostrocaudal position in millimeters of the section 
relative to the obex according to the atlas of the rat subpostremal NTS. 
(7). Microinjection sites for different doses of A1 adenosine receptor 
agonist [N
6
-cyclopentyl adenosine (CPA)], nonselective adenosine 
receptor antagonist [8-sulfophenyl theophylline (8-STP)] & volume 
control [(microinjections of 50 nl of artificial cerebrospinal fluid (ACF)] 
were marked with fluorescent dye. A: ■, 0.033 pmol CPA; ▲, 1 nmol 8-
SPT; , volume control.  B: ●, 3.3 pmol CPA; ○, 330 pmol CPA. 
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diagrams based on the atlas of the rat subpostremal NTS by Barraco et al. (7). 
Cardiopulmonary chemoreflex stimulus-response curves 
The cardiopulmonary chemoreflex-responses were evoked using intra-atrial 
infusions of increasing doses (1-8 g/kg) of the serotonin 5HT3 receptor agonist, 
phenylbiguanide (Sigma, 20 g/1ml solution in 0.9% NaCl).  This is a standard, 
experimentally well controlled method of activation of polymodal 
chemosensitive/mechanosensitive cardiopulmonary receptors used in most of the 
studies in the field (19; 38; 40; 52; 57; 95; 100; 101; 130).  To minimize and unify the 
effects of receptor adaptation across the experimental conditions, the injections were 
always performed in increasing order of doses of PBG with 2.5 min intervals between 
the doses, similarly as it was done previously (100; 101).  Total time to complete the 
stimulus-response curve was ~ 8 min.  The stimulus-response curves were obtained 
under control conditions, then at least 30 min later, approximately 5 min after bilateral 
microinjections of drugs (CPA or 8-SPT) or vehicle into the caudal NTS, and again 60 
min after the microinjections of CPA (recovery).  Preliminary experiments showed that 
two stimulus-response curves obtained under control condition in half an hour interval 
revealed similar reactivity of the reflex.  This approach allowed to assess 
cardiopulmonary chemoreflex reactivity during the most effective action of NTS 
adenosine A1 receptor activation: the maximal hemodynamic and neural responses 
evoked by stimulation of A1 adenosine receptors in the NTS with microinjection of CPA 
(330 pmol/50 nl) occur approximately 10-20 min after the microinjection (71; 107).   
Data analysis 
The cardiopulmonary reflex stimulus-response curves for MAP, HR and the 
regional sympathetic outputs under control conditions were compared with those 
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generated after bilateral stimulation of NTS A1 adenosine receptors, nonselective 
blockade of A1 + A2a adenosine receptors, and microinjection of vehicle into the NTS.  In 
a separate set of analysis control reflex stimulus-response curves obtained before 
microinjections of CPA were also compared with those generated ~70 min after the 
microinjections (recovery).  The maximal reflex responses in all measured variables 
were compared between the experimental conditions.  The level of inhibition of the 
reflex responses exerted by different levels of activation of NTS A1 receptors (volume 
control and three doses of CPA) was calculated according to the equation: (control 
response - response after the microinjection into the NTS)/control response x 100%. A 
100% inhibition reflected complete abolition of the response. 
The analysis of variance and significance of differences between mean values 
were calculated using the statistical package SYSTAT version 11 (SYSTAT Software 
Inc., Richmond, CA, USA).  Two-way ANOVA for repeated measures was used to 
compare the reflex responses of each variable across the experimental conditions 
(control vs. microinjection and control vs. recovery) and across four levels of activation 
of the cardiopulmonary reflex (four doses of PBG, 1-8g/kg).  Two-way ANOVA for 
repeated measures was also used to compare simultaneously recorded three nerve 
responses (RSNA vs. pre-ASNA vs. LSNA) evoked by four doses of PBG, whereas for 
comparison of different nerves and components of the adrenal nerve responses (RSNA 
vs. pre-ASNA vs. int-ASNA vs. post-ASNA vs. LSNA) and four doses of PBG a two-way 
ANOVA for independent measures was used.  Two-way ANOVA for independent 
measures was also used to analyze the reflex responses evoked by volume control 
(ACF) and three doses of CPA (0.033-330 pmol) for the three sympathetic outputs 
(RSNA vs. LSNA vs. pre-ASNA) at each level of activation of the cardiopulmonary 
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chemoreflex.  If significant interactions were found (nerve × experimental condition and 
nerve × dose), the differences between the means were calculated with a modified 
Bonferroni t-test.  One-way ANOVA for independent measures followed by modified 
Bonferroni t-test was used for comparison of HR and MAP responses evoked by 
microinjections of ACF and the three doses of adenosine receptor antagonist, CPA.  
The changes in baseline levels of MAP, HR, RSNA, LSNA and pre-ASNA evoked by 
bilateral microinjections of three doses of CPA, the adenosine receptor antagonist, and 
the respective volume of vehicle were calculated as a difference between baseline 
values averaged during the last 30 s preceding the microinjections and the last 30 s of 
the 5 min period of the response to microinjections measured before generating the 
second cardiopulmonary chemoreflex stimulus response curve.  An α-level of P < 0.05 
was used to determine statistical significance. 
RESULTS 
Basal MAP and HR measured before the control cardiopulmonary chemoreflex 
stimulus-response curves in each animal (n = 57) were 88.0 ± 1.6 mmHg and 392.7 ± 
6.8 beats·min-1, respectively.  Approximately 35 min after the control stimulus-response 
curves, the basal parameters, measured just before microinjections into the NTS of 
selective A1 adenosine receptor agonist (CPA), nonselective A1 + A2a receptors 
antagonist (8-SPT) or vehicle (ACF) returned toward normal levels: 89.8 ± 1.7 mmHg 
and 383.8 ± 6.3 beats·min-1 for MAP and HR, respectively.  Also, in those animals in 
which the third stimulus response curve was performed ~60 min after the 
microinjections of CPA (recovery, n = 35), basal MAP and HR were similar to those 
measured at the beginning of the experiment (85.9 ± 1.5 mmHg and 366.4 ± 8.1 
beats·min-1, respectively).  There were no substantial differences between these three 
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basal levels.  The effects of bilateral microinjections of three doses of selective A1 
adenosine receptor agonist (CPA, 0.033, 3.3 and 330 pmol in 50 nl, n=10, 13 and 14, 
respectively), nonselective A1 + A2a adenosine receptor antagonist, 8-SPT, 1 nmol in 
100 nl, n=9), and vehicle (ACF, 50 nl, n=11) on resting hemodynamic and neural 
variables are  presented  in  Table 1.  Inasmuch as   most of the effects of A1 receptor  
Table 1. Changes in baseline values following A1 receptor agonist and nonselective adenosine antagonist. Baseline 
values of MAP, HR, RSNA, pre-ASNA and LSNA after bilateral microinjection of the selective NTS A1 adenosine 
receptor agonist (CPA), respective volume control, ACF, and nonselective adenosine receptor antagonist 8-SPT. 
 
 
 
Values are means ± SE.  *P < 0.05 vs. ACF; #, P<0.05 vs. RSNA; †, P<0.05 vs. LSNA. 
activation are mediated via modulation of arterial baroreflex integration (102; 107) which 
is abolished by the sino-aortic baroreceptor denervation, the responses to CPA were 
limited similarly to what we previously observed after sino-aortic baroreceptor 
denervation plus vagotomy, i.e. increases in MAP, RSNA and LSNA were virtually 
abolished whereas the increases in pre-ASNA were attenuated (107).  The 
hemodynamic and neural responses evoked by bilateral microinjections of adenosine 
receptor antagonist (8-SPT) and vehicle (ACF), performed in the present study in 
sinoaortic denervated animals, were accentuated compared to the responses observed 
in intact animals (54). 
 
Cardiopulmonary chemoreflex differentially inhibits regional sympathetic outputs 
An example of original recordings of hemodynamic and neural responses evoked 
by increasing activation of cardiopulmonary chemoreflex under control conditions is 
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presented  in  Figure  4  (left panels).    
Figure  5   presents   averaged   control  
cardio-pulmonary chemoreflex curves.  
Gradual activation of cardiopulmonary 
receptors via increasing doses of PBG 
(1-8 g/kg) evoked dose dependent 
decreases in MAP and HR and 
differential decreases in regional 
sympathetic nerve activity (RSNA>pre-
ASNA>LSNA).  Figure 5A presents 
combined double and triple nerve 
recordings (RSNA, pre-ASNA, int-ASNA, 
post-ASNA and LSNA).  Two way 
ANOVA for independent measures 
showed that the regional sympathetic 
outputs were inhibited to a different 
degree (nerve factor, p<0.001) and that 
the steepness of reflex stimulus 
response curves (Figure 5A) were different across the nerves (PBG dose vs. nerve 
interaction, p=0.003).  Interestingly, no differences were observed between the 
responses of different components of the adrenal nerve: pre-ASNA, int-ASNA and post 
ASNA (PBG dose vs. nerve interaction p=0.913) although the responses of each of the 
components were significantly different from the responses in RSNA and LSNA.  
Therefore pre-ASNA (n=37) and int-ASNA (n=6) were combined for further calculations 
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Figure 4. Example of the reflex responses under control 
conditions and following adenosine A1 receptor activation. 
Cardiopulmonary chemoreflex responses of mean arterial 
pressure (MAP), heart rate (HR), renal (RSNA) and 
preganglionic adrenal (pre-ASNA) and lumbar (LSNA) 
sympathetic nerve activity evoked by increasing doses of 
phenylbiguanide into the right atrium under control 
conditions (left panels) and following stimulation of NTS A1 
adenosine receptors with the highest dose of the selective 
agonist, CPA (330 pmol in 50 nl). All recording were 
performed in one animal. The blockade of A1 adenosine 
receptors in the NTS virtually abolished the reflex 
responses. 
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and considered as a predominantly preganglionic-ASNA (activity remaining after the 
ganglionic blockade >50%).  Predominantly postganglionic ASNA (n=4) was excluded 
from further calculations. 
The comparison of control neural 
responses recorded in all 57 animals 
(Figure 5A, double and triple nerve 
recordings combined) yielded very 
similar results to those where 3 
sympathetic outputs (RSNA, pre-ASNA 
and LSNA) were recorded 
simultaneously (Figure 5B, n=21).  The 
results of two way ANOVA for the triple 
nerve recordings only (repeated 
measures, nerve factor, p<0.001, PBG 
dose vs. nerve interaction p=0.001) 
(Figure 5B) were very similar to those 
obtained for all combined neural 
recordings (Figure 5A) (nerve factor, 
p<0.001, PBG dose vs. nerve 
interaction p=0.003). This attests that 
the reflex responses recorded from two 
or three sympathetic outputs under the 
same experimental conditions were 
fully comparable.  
Figure 5. Averaged cardiopulmonary chemoreflex 
responses to PBG. Hemodynamic and regional neural 
responses evoked by gradual stimulation of 
cardiopulmonary receptors with increasing doses of 
phenylbiguanide. A: combined all neural recordings 
performed in 57 animals from lumbar  (39) 
preganglionic adrenal (37), intermediate adrenal (6) 
postganglionic adrenal (4) and renal (56) sympathetic 
nerves; number of recordings from each nerve in 
parentheses. B: simultaneous neural recordings from 
renal, preganglionic adrenal and lumbar sympathetic 
nerves performed in 21 animals. MAP, mean arterial 
pressure; HR, heart rate; SNA, sympathetic nerve activity. 
Data are means ± standard error.  Statistical differences, 
P<0.05: *, vs. preganglionic adrenal; ‡, vs. intermediate 
adrenal †, vs. postganglionic adrenal; #, lumbar vs. renal. 
There were no significant differences between the 
responses of different components of the adrenal nerve. 
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A1 adenosine receptors inhibit cardiopulmonary chemoreflex mechanism at the 
level of the NTS 
The example of original recordings (Figure 4) shows powerful inhibition of 
cardiopulmonary reflex responses following bilateral activation of NTS A1 adenosine 
receptors with the maximal dose of CPA (330 pmol).  This effect was dose dependent 
as shown in Figure 6.   The stimulus  response curves  were gradually  flattened as  the 
 
dose of A1 adenosine receptor agonist (CPA) increased.  The smallest dose of the 
agonist (CPA, 0.033 pmol) significantly attenuated the reflex control of renal and lumbar 
sympathetic outputs and tended to inhibit pre-ASNA reflex responses (control vs. 
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Figure 6. Comparisons of the reflex responses obtained under control 
and CPA conditions. Cardiopulmonary reflex responses obtained under control conditions vs. the responses 
obtained following volume control (ACF), increasing doses of A1 adenosine receptor agonist (CPA) and adenosine 
receptor antagonist (8-SPT) .  Data are means ± standard error. MAP, mean arterial pressure; HR, heart rate; 
RSNA, renal, ASNA, preganglionic adrenal, LSNA, lumbar sympathetic nerve activity. *, P<0.05 vs. control.  
Increasing activation of A1 adenosine receptors gradually inhibited the reflex responses.  Adenosine receptor 
antagonist and volume control did not alter the reflex responses. 
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experimental conditions effect, p=0.098).  No attenuation of MAP and HR reflex 
responses were observed in this setting (control vs. experimental conditions effects, 
p=0.469 and p=0.889, respectively).  Greater activation of NTS A1 receptors (CPA, 3.3 
and 330 pmol) evoked gradual and significant attenuation the reflex responses of all 
variables at all levels of activation of the cardiopulmonary chemoreflex.  Comparisons 
across the nerves (renal, preganglionic adrenal and lumbar) and doses of CPA (from 0, 
volume control, to 330 pmol) 
showed that the nerves responded 
differentially to activation of the 
reflex (nerve effect, p<0.0001) and 
were inhibited by A1 adenosine 
receptor agonist in a dose 
dependent manner (CPA dose 
effect, p<0.0001).  However, the 
inhibition of the reflex responses in 
all sympathetic outputs was similar 
(no significant nerve vs. CPA dose 
interaction).  Microinjections of 
vehicle (ACF) or adenosine 
receptor antagonist (8-SPT) did 
not affect the reflex responses (far 
left and right panels of Figure 6, 
respectively).   
Figure 7 shows the level of inhibition of the cardiopulmonary chemoreflex after 
Figure 7. The inhibition of the control reflex responses evoked by A1 
receptor activation. Hemodynamic and regional sympathetic reflex 
responses evoked by volume control (ACF) and the increasing 
doses of adenosine A1 receptor agonist, CPA microinjected into the 
NTS at four different levels of activation of the reflex (intra-atrial 
injections of phenylbiguanide, PBG, 1-8 g/kg). Data are means ± 
standard error. SNA-sympathetic nerve activity of renal, 
preganglionic adrenal and lumbar nerves. CPA exerted significant, 
dose dependent inhibition of the reflex responses at all levels of 
activation of the reflex, *, P<0.05. No significant differences between 
the inhibition of regional sympathetic responses were found. 
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activation of NTS A1 adenosine receptors and respective volume control.  Inhibition was 
quantified as the % reduction in the control response; therefore 100% inhibition 
corresponds to a completely abolished response.  The cardiopulmonary chemoreflex 
responses of all recorded variables were inhibited in dose dependent manner at each 
level of activation of the reflex (highly significant CPA dose effects) (Figure 7).  
However, no significant differences in the inhibition of the three regional sympathetic 
outputs were found (nerve effects, p>0.05 for all comparisons).  Thus, whereas 
cardiopulmonary chemoreflex activation elicits markedly differential reductions in 
regional sympathetic nerve activity, NTS A1 receptor stimulation inhibits these 
responses in a uniform fashion.  This inhibition was reversible.  Table 2 shows that the 
reflex responses completely recovered approximately 60 min after microinjections of the 
small and medium doses of CPA into the NTS and tended to recover after the highest 
dose (330 pmol) of the agonist (compare Table 2 and Figure 7). 
 
DISCUSSION 
The most important finding of the present study is that adenosine operating via 
A1 receptors within the NTS powerfully inhibits the cardiopulmonary chemoreflex.  In 
Table 2. Averaged cardiopulmonary chemoreflex responses to PBG evoked under control conditions and 1 hour 
after microinjection of A1 adenosine receptor agonist CPA 
Values are means ± SE.   *P<0.05 vs. control. 
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addition, direct comparison of simultaneously recorded renal, adrenal, and lumbar 
sympathetic responses showed that activation of cardiopulmonary chemoreceptors 
exerts regionally different inhibition of these sympathetic outputs (RSNA>pre-
ASNA>LSNA).  Despite of the highly significant differences between cardiopulmonary 
chemoreflex inhibition of the regional sympathetic outputs, the attenuation of the 
cardiopulmonary chemoreflex responses by stimulation of NTS A1 adenosine receptors 
was similar across the sympathetic outputs (RSNA=pre-ASNA=LSNA). Activation of the 
CCR evoked the greatest sympathoinhibition in RSNA but smaller in pre-ASNA and the 
smallest in LSNA. Stimulation of NTS A1 adenosine receptors inhibited differential CCR 
responses in renal, adrenal and lumbar sympathetic outputs to a similar extent. 
Potential mechanisms 
Adenosine operates in the NTS under both physiological and pathological 
conditions.  For example, during the hypothalamic defense response adenosine is 
released into the NTS (30) and contributes to the pressor component of this response 
via activation of A1 receptors (35; 116; 118).  Adenosine is also released into the central 
nervous system, including the NTS during ischemia, hypoxia or severe hemorrhage (87; 
110; 129; 138; 139).  Activation of presynaptic A1 adenosine receptors in the central 
nervous system inhibits the release of transmitters from nerve terminals; central 
neurons may also be directly inhibited via postsynaptic A1 adenosine receptors (90).  In 
the NTS A1 adenosine receptors are present on presynaptic afferent terminals and in 
somato-dendritic locations (63).  The present study confirmed our hypothesis that 
adenosine operating via A1 receptors may inhibit neurotransmission in cardiopulmonary 
chemoreflex pathway at the level of the NTS.  These data are consistent with previous 
studies from our laboratory which showed that stimulation of NTS A1 adenosine 
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receptors uniformly resets the baroreflex curves for renal, adrenal and lumbar 
sympathetic nerve activity toward higher arterial pressure most likely via inhibition of 
glutamatergic transmission in this reflex pathway (102; 107).  The arterial baroreflex and 
cardiopulmonary chemoreflex are mediated via similar neural pathways and glutamate 
serves as a primarily neurotransmitter in both reflexes (131).  Therefore, the powerful 
inhibition of cardiopulmonary chemoreflex responses due to activation of NTS A1 
adenosine receptors was mediated probably via inhibition of glutamate release in this 
reflex pathway at the level of the NTS.  Interestingly, the attenuation of cardiopulmonary 
chemoreflex responses in renal and lumbar sympathetic outputs was already significant 
at the lowest level of activation of A1 adenosine receptors (CPA, 0.033 pmol) whereas 
hemodynamic and adrenal responses were not yet significantly attenuated at this 
concentration of the agonist (Figure 6, second column of graphs).  This lower threshold 
for adenosine A1 receptor mediated inhibition of renal and lumbar reflex responses may 
be a result of differential location/expression of A1 adenosine receptors on NTS neurons 
targeting sympathetic outputs directed to different vascular beds and organs. 
Stimulation of NTS A1 adenosine receptors differentially increases baseline 
sympathetic nerve activity: pre-ASNA>RSNA≥LSNA (107).  The renal and lumbar 
sympathoexcitation was abolished via bilateral sinoaortic denervation combined with 
vagotomy; the adrenal sympathoexcitation was attenuated in this setting (107).  
However, it was unknown if arterial baroreflex afferents or vagal afferents or both 
contributed to the sympathoexcitation evoked by stimulation of A1 adenosine receptors 
in the NTS.  The present study showed that the sinoaortic denervation alone had very 
similar effect on baseline shifts of these sympathetic outputs compared to the effect of 
combined sinoaortic denervation plus vagotomy [compare Table 1 and ref (107)].  This 
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indicates that the sympathoexcitation produced by A1 receptor stimulation, previously 
observed in animals with all afferents intact, is mediated via A1 adenosine receptor 
inhibition of baroreflex but not cardiopulmonary chemoreflex pathway.  Whereas, both 
sympathoinhibitory reflexes are powerfully inhibited by activation of NTS A1 adenosine 
receptors the cardiopulmonary chemoreflex has little if any tonic activity thus inhibition 
of the arterial baroreflex is most likely responsible for the effects of NTS A1 adenosine 
receptor stimulation in animals with all afferents intact.  Collectively, the present and 
previous results would support the concept that during stress or the hypothalamic 
defense response, adenosine released within the NTS and operating via A1 receptors 
(30; 35; 116; 118) may inhibit sympathoinhibitory reflexes (arterial baroreflex and 
cardiopulmonary chemoreflex). 
It was not surprising that blockade of adenosine receptors in the NTS did not 
affect the cardiopulmonary chemoreflex responses.  Adenosine is released into the NTS 
mostly in specific physiological or pathological situations (stress, hypoxia, ischemia, 
severe hemorrhage) (30; 87; 110; 118; 129; 138; 139).  Therefore under normal 
conditions the tonic effects of adenosine are minimal if any.  Our previous studies and 
reports from other laboratories showed very weak or no effects of blockade of 
adenosine receptors under resting, normal conditions.  However, the blockade of A2a or 
A1+ A2a receptors in the NTS markedly alters the pattern of autonomic responses to 
severe hemorrhage, a pathological condition during which adenosine levels increase in 
the central nervous system (110; 129).  Summarizing, naturally released adenosine may 
have little or no effect on cardiovascular reflexes integrated in the NTS under normal 
conditions; however, adenosine neuromodulation may become important during 
pathological conditions when ischemia and hypoxia reach the NTS (87; 110; 129; 138; 
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139).  This is consistent with the hypothesis that adenosine may serve as a negative 
feedback regulator for the Bezold Jarisch reflex only under pathological conditions, i.e. 
when the reflex causes life threatening hypotension which exceeds compensatory 
capability of brainstem autoregulation and adenosine is released into the NTS.  It should 
be stressed that this reflex is naturally activated and enhanced during cardiac ischemia 
(17; 67; 83; 93) and the role of centrally released adenosine in modulation of cardiac 
ischemia is unknown . 
Differential inhibition of regional sympathetic outputs by cardiopulmonary 
chemoreflex 
The present study showed that under the same experimental conditions the 
Bezold-Jarisch reflex exerts a differential inhibition of regional sympathetic outputs 
(RSNA>pre-ASNA>LSNA).  This differential pattern of regional sympathoinhibition was 
similar to that previously observed with stimulation of arterial baroreceptors under 
similar experimental conditions (54; 99; 102).  This is consistent with the hypothesis that 
similar central pathways mediate both reflexes (131).  The renal nerve is functionally 
consistent as it facilitates pressor responses via vasoconstriction, increase of sodium 
reabsorption and release of renin (39); all these components are inhibited by stimulation 
of arterial baroreceptors and perhaps cardiopulmonary chemoreceptors.  In the adrenal 
nerve ~25% of fibers directed  to norepinephrine containing chromaffin cells do not 
respond to cardiopulmonary chemoreflex stimulation (19).  In addition to 
vasoconstricting  fibers lumbar sympathetic nerve provides vasodilating fibers and also 
a substantial number of cutaneous fibers which do not respond strongly to the arterial 
baroreflex (33; 49) and likely cardiopulmonary chemoreflex stimuli, as suggested by the 
present study.  Therefore the differential regional sympathoinhibition observed in the 
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present study may be a result of the differential composition of these three nerves.  
Interestingly, within the adrenal nerve there were no significant differences between the 
different components, although preganglionic and postganglionic outputs to the adrenal 
medulla often respond in a reciprocal manner to other stimuli (20; 21; 105).  Although 
qualitatively similar regional sympathetic responses evoked by stimulation of 
cardiopulmonary receptors with PBG were reported previously (19; 38; 95; 100) this is 
the first study which allows for quantitative comparisons of the regional sympathetic 
responses recorded under identical experimental conditions (simultaneous triple nerve 
recordings).   
There are only few controversial reports on cardiopulmonary chemoreflex control 
of pre-ASNA and LSNA.  For example, increases in adrenal nerve activity were reported 
in response to intra pericardial infusions of phenylbiguanide (52).  It is likely, that the 
activation of a subset of epicardiac serotonin 5HT3 receptors increases pre-ASNA (52); 
however, this effect is overwhelmed by activation of all cardiopulmonary chemoreflex 
receptors via intra-atrial injections of the agonist.  In two other studies typical decreases 
in RSNA were accompanied with increases in pre-ASNA and no responses from LSNA 
(40; 130).  In both these studies intravenous instead intra-atrial infusions of PBG were 
performed and experiments were conducted under methohexial instead of 
urethane/chloralose anesthesia.  Since PBG injected into the femoral vein may be 
markedly diluted before reaching the cardiopulmonary area and taking into 
consideration that RSNA is inhibited to a much greater extent than LSNA, it is possible 
that the stimulation threshold for RSNA inhibition but not LSNA inhibition was reached in 
this study (130).  It is more difficult to explain the increases in adrenal nerve activity 
observed in response to intravenous infusion of PBG (40); perhaps, the infusion of PBG 
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into the femoral vein and methohexial anesthesia could be responsible. 
A recent study from McAllen's laboratory showed that in contrast to typical 
inhibition of RSNA, cardiac sympathetic activity increases in response to stimulation of 
cardiopulmonary receptors with PBG, although the reflex cardiac slowing prevail 
indicating simultaneous activation of vagal inhibition of the heart (95).  Even though 
increase in parasympathetic control of the heart may be cardio-protective; simultaneous 
increase in  sympathetic component increases the probability of cardiac arrhythmia, 
especially in the ischemic heart, a condition where the cardiopulmonary chemoreflex is 
naturally activated (67; 93).  This potentially cardio-arrhythmic scenario is partially 
counteracted by inhibition of the adrenal medulla and decreased humoral activation of 
the heart as sympathetic outputs to both epinephrine and norepinephrine releasing 
chromafin cells are inhibited by the reflex (19).   
Limitations of the method 
The method of evoking the cardiopulmonary chemoreflex via intra-atrial infusion 
of PBG is widely accepted in the field (19; 38; 40; 52; 57; 95; 100; 101; 130) and allows 
for precise experimental control of the levels of activation of the reflex in dose 
dependent manner.  It should be stressed that the cardiopulmonary chemoreflex is 
mediated via polymodal vagal afferent fibers.  For example, the majority of cardiac vagal 
afferents responding to mechanical stimulation respond also to PBG (101).  Many other 
substances may activate the cardiopulmonary chemoreceptors during cardiac ischemia 
and the early phase of infarct (for example, ATP via P2x receptors, amadamine via 
vanilloid TRPV1 receptors, nicotine, etc) (44; 67; 85; 93).  Therefore the serotonin 5HT3 
receptor agonist, PBG, may serve as a convenient tool for experimental dissection of 
the Bezold Jarisch reflex from other reflexes and humoral mechanisms triggered by 
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cardiac ischemia, for example, bradykinin activated sympathoexcitation mediated via 
sympathetic afferents from the heart (4; 66).   
We used whole nerve adrenal recordings to make feasible simultaneous 
recordings from up to 3 sympathetic outputs.  Therefore our recordings did not allow us 
to distinguish between sympathetic outputs directed to epinephrine vs. norepinephrine 
containing chromafin cells.  However, this is a minor disadvantage as Cao and Morrison 
showed that the cardiopulmonary chemoreflex inhibits both sympathetic outputs; it 
inhibits virtually all spinal neurons projecting to the epinephrinergic chromafin cells and 
~ ¾ neurons supplying norepinephrinergic chromafin cells (19). 
Similarly as in our previous studies we did not use a selective A1 adenosine 
receptor antagonist, as the selective antagonists can be dissolved in dimethyl sulfoxide 
(DMSO) but not in water (54; 110).  Microinjections of DMSO into the NTS evoke 
profound and long lasting decreases in MAP, HR and all the regional sympathetic nerve 
activity (preliminary studies).  Therefore we chose a water soluble, nonselective 
antagonist of adenosine receptor subtypes (8-SPT).  This antagonist effectively blocked 
A1 (and A2a) adenosine receptors in the NTS in a previous study from our laboratory 
(110).  The blockade of adenosine receptor subtypes, performed in the present study 
under normal, physiological conditions, did not have significant effects on responses 
evoked by stimulation of the cardiopulmonary chemoreflex in all recorded hemodynamic 
and neural variables.  Therefore, further quantification of the effect of selective blockade 
of A1 adenosine receptors in the NTS was not necessary.   
Perspectives 
The cardiopulmonary chemoreflex provides regionally specific inhibition of non-
cardiac sympathetic outputs as well as stimulation of parasympathetic activity to the 
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heart (19; 38; 95; 100).  This may be cardio-protective by decreasing cardiac afterload 
and oxygen consumption but may also lead to a dangerous hypotension and 
bradyarrhythmias, fainting and even sudden cardiac death when the cardiopulmonary 
chemoreflex (Bezold Jarisch reflex) is highly activated (68).  Adenosine operating via A1 
receptors in the NTS powerfully inhibits these reflex responses.  Since adenosine is 
released into the central nervous system during hypotensive phase of severe 
hemorrhage (110; 129) it may serve as a negative feedback regulator for the 
cardiopulmonary chemoreflex.  Fine tuning of sympathoinhibitory and 
sympathoexcitatory reflexes originating from vagal cardiopulmonary afferents and 
cardiac sympathetic afferents, respectively, has been previously proposed by Longhurst 
(66).  This parallel tuning of simultaneously activated vagal and sympathetic afferents 
(for example, with serotonin released from aggregating platelets during clot formation in 
coronary arteries) occurs via reciprocal effects of both reflexes on sympathetic outflow 
and arterial pressure as well as via reciprocal inhibition between neuronal pools 
mediating both reflexes in the NTS (66).  The present study demonstrates that this 
parallel tuning mechanism may be supplemented by "the last chance mechanism" of 
negative feedback mediated by adenosine which powerfully inhibits the 
sympathoinhibitory cardiopulmonary chemoreflex preventing life threatening reflex 
hypotension.  Our previous study showed that another sympathoinhibitory reflex, i.e. 
arterial baroreflex, is also inhibited by activation of A1 (but not A2a) adenosine receptors 
in the NTS (54; 102).  Taken together, this suggests that adenosine may play a role of 
universal negative feedback regulator preventing severe hypotension mediated by 
sympathoinhibitory, reflexes primarily integrated in the NTS.  Further studies may show 
if adenosine inhibits or facilitates sympathoexcitatory reflexes integrated in the NTS (for 
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example arterial chemoreflex or sympathetic afferent reflexes). 
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CHAPTER 2 
Paradoxical inhibition of cardiopulmonary chemoreflex control of regional 
sympathetic outputs evoked by activation of NTS A2a adenosine receptors 
ABSTRACT 
Previously we have shown that stimulation of inhibitory NTS A1 adenosine 
receptors attenuates cardiopulmonary chemoreflex (CCR) sympatho-inhibition of renal 
(RSNA), preganglionic adrenal (pre-ASNA) and lumbar (LSNA) sympathetic nerve 
activity and decreases in arterial pressure and heart rate.  We have also shown that 
activation of the facilitatory NTS A2a adenosine receptors has differential effects on the 
baseline levels of these sympathetic outputs; decreasing RSNA, increasing pre-ASNA 
and not changing LSNA.  Therefore, we hypothesized that stimulation of A2a receptors 
will facilitate the CCR evoked decreases in RSNA, but it will not change the CCR 
responses in LSNA and will attenuate the CCR responses in pre-ASNA. In 
urethane/chloralose anesthetized rats (n=38) we compared regional sympathetic 
responses evoked by stimulation of the CCR with right atrial injections of the serotonin 
5HT3 receptor agonist, phenylbiguanide, (PBG 1-8 g/kg) before and after selective 
stimulation or blockade of NTS A2a adenosine receptors (microinjections into the NTS of 
CGS-21680 0.2-20 pmol/50 nl or ZM-241385 40 pmol/100 nl, respectively). Surprisingly, 
we found that the facilitatory A2a adenosine receptors paradoxically inhibited the 
hemodynamic and regional sympathetic reflex responses. The reflex sympathetic 
responses were inhibited uniformly despite of the contrasting shifts in baseline 
sympathetic activity suggesting that these two effects are mediated via different 
mechanisms.  Blockade of NTS A2a receptors virtually did not affect the CCR responses 
indicating little tonic A2a receptor activity.  These data suggest that stimulation of NTS 
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A2a receptors triggers unknown inhibitory mechanism(s) which in turn inhibit 
transmission in the CCR pathway at the level of the NTS. 
INTRODUCTION 
Adenosine operating via A1 and A2a receptors is a powerful central modulator of 
cardiovascular reflexes primarily integrated in the nucleus of the solitary tract (NTS) (1; 
81; 103; 108; 123).  The importance of adenosine neuromodulation occurring in the 
NTS is stressed by the fact that the NTS contains the greatest density of adenosine 
uptake sites in the entire central nervous system (14).  Adenosine is released into the 
NTS during life threatening situations.  During the stress/hypothalamic defense 
response the source of endogenous adenosine is extracellular ATP released from 
descending hypothalamic terminals or activated glial cells and catabolized to adenosine 
by ectonucleotidases (30; 116-118; 142).  In contrast, during severe hemodynamic 
imbalance (ischemia, hypoxia or severe hemorrhage) intracellular ATP is catabolized to 
adenosine inside hypoxic neurons and glial cells and then adenosine is released into 
the extracellular space (87; 129; 138; 139).  Despite this global action, adenosine 
evokes contrasting effects on regional sympathetic outputs and blood pressure control 
via two antagonistic A1 and A2a receptor subtypes which inhibit and activate 
neurotransmitter release and central neurons, respectively (90).  Our previous studies 
showed that selective stimulation of NTS A1 receptors evokes pressor responses and 
differential increases in renal (RSNA), preganglionic adrenal (pre-ASNA), and lumbar 
(LSNA) sympathetic nerve activity (107) mostly via inhibition of baroreflex restraint of 
these sympathetic outputs (102).  In contrast, selective stimulation of NTS A2a receptors 
evokes depressor responses and greatly diverse regional sympathetic responses: 
decreases in RSNA, increases in pre-ASNA, and no changes in LSNA (104; 105).  
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These highly contrasting effects of adenosine receptor subtypes on regional 
cardiovascular control most likely are the result of differential localization of A1 and A2a 
receptors on NTS interneurons which finally target different sympathetic outputs as we 
proposed previously (103; 108).    
Our most recent paper showed that stimulation of NTS A1 adenosine receptors 
inhibited the cardiopulmonary chemoreflex (CCR)-mediated regional sympathetic 
responses in a uniform way, although this reflex (also known as the Bezold Jarisch 
reflex) evoked differential regional sympathoinhibition (RSNA>pre-ASNA>LSNA) (53).  
The Bezold-Jarisch reflex is a powerful depressor, cardiac slowing and 
sympathoinhibitory reflex activated by polymodal mechano- and chemoreceptors which 
transmit information from the cardiopulmonary area to the NTS via unmyelinated vagal 
C fibers in the rat (26; 84; 85; 124-126).  Powerful activation of this reflex may contribute 
to fainting and is even blamed for some episodes of sudden cardiac death in young 
athletes (13; 48; 68).   
Since A2a adenosine receptors, which dominate in the NTS, usually exert 
opposite effects to those evoked by A1 receptors we anticipated that selective activation 
of NTS A2a receptors may differentially facilitate the CCR.  This was likely because the 
same pattern of changes in regional sympathetic outputs that are observed with 
stimulation of A2a receptors (104; 105) has also been reported occasionally with 
activation of the CCR; e.g., increases in pre-ASNA, decreases in RSNA and no 
changes in LSNA (40; 52; 130).  However, the majority of previous reports and our most 
recent study indicated that CCR differentially inhibits the regional sympathetic nerve 
activity (RSNA>ASNA≥LSNA) (19; 38; 53; 95; 100; 131).  Therefore, considering the 
diverse pattern of regional sympathetic responses to stimulation of NTS A2a receptors, 
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we hypothesized that stimulation of these receptors may facilitate CCR responses to a 
greater extent in RSNA than LSNA.  In contrast, pre-ASNA reflex responses may be 
even attenuated as activation of A2a adenosine receptors and CCR afferents exerts the 
opposite effects on this sympathetic output.   
We compared the regional sympathetic responses evoked by gradual activation 
of CCR afferents before and after stimulation of NTS A2a adenosine receptors with 
increasing doses of the selective agonist (CGS-21680).  We also investigated the effect 
of inhibition of these receptors with the selective antagonist (ZM-241385) to test 
whether A2a receptors are tonically active in the CCR pathway.  To our surprise, instead 
of differential facilitation of CCR control of regional sympathetic outputs we observed 
paradoxical, uniform inhibition of all regional sympathetic reflex responses similar to that 
observed previously with stimulation of antagonistic A1 adenosine receptors in the NTS 
(53).    
METHODS 
All protocols and surgical procedures employed in this study were reviewed and 
approved by the Institutional Animal Care and Use Committee and were performed in 
accordance with the Guide for the Care and Use of Laboratory Animals endorsed by the 
American Physiological Society and published by the National  Institutes of Health. 
Design 
We compared regional sympathetic (renal, adrenal, and lumbar) and 
hemodynamic (heart rate, HR, and mean arterial pressure, MAP) responses evoked by 
graded stimulation of the cardiopulmonary chemoreceptors before and after selective 
activation or inhibition of NTS A2a adenosine receptors
 in a total of 38 male Sprague-
Dawley rats, weight = 367.4 ± 6.3 g.  In 29 rats, the comparisons were made between 
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CCR stimulus response function curves obtained under control conditions and 
approximately 5 min after microinjections into the NTS of three different doses of the 
selective A2a adenosine receptor agonist, CGS-21680, (0.2, 2.0, and 20 pmol in 50 nl; 
numbers of animals in each group were 10, 10 and 9, respectively).  In an additional 9 
rats the CCR function curves were compared before and ~ 5 min after inhibition of NTS 
A2a adenosine receptors with a water soluble, selective A2a receptor antagonist; ZM-
241385 (40 pmol in 100 nl).  The CCR reactivity was also assessed approximately one 
hour after the pharmacological manipulations in the NTS (recovery) in 36 rats; in two of 
them the evaluation of the recovery reflex curves was impossible for technical reasons. 
The timeline of the protocol is presented in Figure 8. 
 
Instrumentation and measurements 
All procedures were described in detail previously (53; 100; 105-107).  Briefly, 
male Sprague-Dawley rats (Charles River) were anesthetized with a mixture of α-
chloralose (80 mg·kg-1) and urethane (500 mg·kg-1 i.p.), tracheotomized, connected to a 
small-animal respirator (SAR-830, CWE, Ardmore, PA), and artificially ventilated with 
40% oxygen, 60% nitrogen mixture.  Arterial blood gases were tested occasionally 
(Radiometer, ABL500, OSM3), and ventilation was adjusted to maintain Po2, Pco2, and 
Figure 8. Timeline of CSG-21680 experiments. Small arrows indicate bolus injections of PBG in increasing doses 
(1-8 g/kg) into the right atrium in 2.5 min intervals. Double large arrows represent bilateral microinjections into 
the NTS of: A2a adenosine receptor agonist CGS-21680 (0.2, 2 and 20 pmol in 50 nl), and selective A2a 
adenosine receptor antagonist, ZM-241385 (40 pmol in 100 nl).  
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pH within normal ranges.  Average values measured at the end of each experiment 
were: Po2 = 153.1 ± 8.1 Torr, Pco2 = 33.7 ± 1.2 Torr and pH = 7.4 ± 0.01.  The left 
femoral artery and vein were catheterized to monitor arterial blood pressure; infuse 
drugs and to supplement anesthesia (12–21 mg·kg-1·h-1 of α-chloralose and 76–133 
mg·kg-1·h-1 of urethane dissolved in 2.4–4.2 ml·kg-1·h-1 saline), respectively.  An 
additional catheter was inserted into the right atrium via the right jugular vein for intra 
atrial PBG injections.  The appropriate position of the catheter in the right atrium was 
confirmed post mortem.  Sinoaortic denervation was performed and tested similarly as 
in the previous studies from our laboratory; special attention was given to preserve the 
vagus nerve intact (53; 100; 105; 107).  
Neural recordings 
In each experiment, simultaneous recordings from three (n=35) or two 
sympathetic outputs (n=3) were performed.  Renal and adrenal nerves were exposed 
retroperitoneally form a flank incision, whereas lumbar sympathetic trunk was exposed 
from midabdominal incision.  Neural recordings were accomplished as described 
previously (53; 100; 105-107).  Neural signals were initially amplified (2,000–20,000×) 
with bandwidth set at 100–1,000 Hz, digitized, rectified, and averaged in 1-s intervals.  
Background noise was determined after the animal was euthanized yet artificially 
ventilated to leave unaltered any potential movement artifacts.  Resting level of the 
nerve activity was normalized to 100% before each stimulation of the cardiopulmonary 
receptors. 
The ratio between preganglionic and total nerve activity was initially tested with 
an intravenous bolus injection of the short-lasting (1-2 min) ganglionic blocker, Arfonad 
(trimethaphan, 2 mg·kg-1; Hoffmann-La Roche), and finally evaluated at the end of each 
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experiment with hexamethonium (20 mg·kg-1 i.v.).  RSNA was almost completely 
postganglionic; 9.2 ± 2.6% (n = 38) of the activity persisted after the ganglionic 
blockade; LSNA was predominantly postganglionic; 41.4 ± 5.1% (n = 37) of 
preganglionic activity remained after the blockade.  Of total of 36 adrenal nerves 
recorded 22 were predominantly preganglionic pre-ASNA (>75% of activity remained 
after the ganglionic blockade), 4 predominantly postganglionic post-ASNA (<50% of 
activity remained after the ganglionic blockade) and 10 had intermediate composition, 
int-ASNA (50%-75% of activity remained after the ganglionic blockade).  Average levels 
of preganglionic, intermediate, and postganglionic adrenal nerve activity after ganglionic 
blockade were: 103.8 ± 8.4, 65.4 ± 3.1, 23.3 ± 5.9%, respectively.  Similarly as in our 
previous study predominantly postganglionic ASNA was excluded from further 
calculations whereas pre-ASNA (n=22) and int-ASNA (n=10) were combined as 
predominantly preganglionic ASNA (>50% of activity remained after the ganglionic 
blockade) (53).  Nevertheless, a separate comparison of the effects of adenosine A2a 
receptor agonist and antagonist on all components of the adrenal nerve was also 
performed (n=36).  The arterial pressure and neural signals were digitized and recorded 
with a Hemodynamic and Neural Data Analyzer (Biotech Products, Greenwood, IN), 
averaged over 1-s intervals, and stored on the hard disk for subsequent analysis. 
Microinjections into the NTS   
Bilateral microinjections of three different doses of the selective A2a receptor 
agonist, CGS-21680 (0.2, 2 and 20 pmol in 50 nl of ACF), and the antagonist, ZM-
241385 (40 pmol in 100 nl of ACF), were made with multibarrel glass micropipettes into 
the medial region of the caudal NTS as described previously (9; 53; 105; 107).  The 
doses and volumes of the agonist and antagonist were the same as used in our 
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previous studies (53; 54; 
102; 106; 107; 110).  The 
drugs were dissolved in ACF 
with pH adjusted to 7.2; the 
selective A2a adenosine 
receptor agonist CGS-21680 
often precipitates in a pH 
>7.2.  All microinjection sites 
were marked with DiI 
lypophilic dye (Molecular 
Probes, CA) and verified 
histologically as described 
previously (9; 53; 105; 107).  
The microinjection sites are presented in Figure 9 using diagrams based on the atlas of 
the rat subpostremal NTS by Barraco et al. (7). 
Cardiopulmonary chemoreflex stimulus-response curves   
The CCR stimulus-response curves were generated as described in our previous 
studies (53; 100; 101).  Briefly, the cardiopulmonary receptors were stimulated using 
bolus injections into the right atrium of increasing doses (1-8 g/kg) of serotonin 5HT3 
receptor agonist, phenylbiguanide (PBG, Sigma, 20 g/1ml solution in 0.9% NaCl) in 2.5 
min intervals between the injections.  Total time to complete the stimulus-response 
curve was ~ 8 min.  The curves were obtained under control conditions; 30 min later, 
approximately 5 min after bilateral microinjections of drugs (CGS-21680 or ZM-241385) 
into the caudal NTS, and again 60 min after the microinjections, recovery (Figure 8).  
Figure 9. Microinjection sites in the subpostremal NTS for all CGS-
21680 experimental groups. AP, area postrema; c, central canal; 10, 
dorsal motor nucleus of vagus nerve; 12, nucleus of hypoglossal nerve; 
Ts, tractus solitarius; Gr, gracile nucleus; Cu, cuneate nucleus. Scale is 
shown at the bottom; number on the left of schematic diagram denotes 
the rostrocaudal position in millimeters of the section relative to the 
obex according to the atlas of the rat subpostremal NTS (7). Bilateral 
microinjection sites for different doses of A2a receptor agonist, CGS-
21680 and A2a receptor antagonist, ZM-241385 were marked with 
fluorescent dye. A: , 0.2 pmol CGS-21680; , 2 pmol CGS-21680; B: 
, 20 pmol CGS-21680, , 40 pmol ZM-241385. 
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This approach allowed assessment of the CCR reactivity during the most effective 
action of the NTS adenosine A2a receptor activation which occurs ~ 5-15 min after the 
microinjection of the agonist (105; 106). 
Data analysis 
The cardiopulmonary reflex stimulus-response curves constructed for MAP, HR 
and the regional sympathetic outputs under control conditions were compared with 
those generated after bilateral stimulation/inhibition of NTS A2a adenosine receptors 
with microinjections of selective agonist and antagonist, CGS-21680 and ZM-241385, 
respectively.  Control reflex stimulus-response curves obtained before microinjections of 
CGS-21680 or ZM-241385 were also compared with the functions generated ~60 min 
after the microinjections (recovery).  The maximal reflex responses in all measured 
variables were compared between the experimental conditions. The effects exerted by 
different levels of activation of NTS A2a receptors (three doses of CGS-21680, 0.2, 2.0, 
and 20 pmol) on the reflex responses were calculated according to the equation: 
[(control response - response after the microinjection into the NTS)/control response] x 
100%.  100% inhibition reflects complete abolition of the response, whereas negative 
values represent facilitation of the reflex responses. The same equation was used to 
calculate the effect of inhibition of NTS A2a receptors (ZM-214385) on the reflex 
responses. 
The data were analyzed using the statistical package SYSTAT version 11 
(SYSTAT Software Inc., Richmond, CA, USA).  Two-way ANOVA for repeated 
measures was used to compare the reflex responses of each variable across the 
experimental conditions (control vs. microinjection and control vs. recovery) and across 
four levels of activation of the CCR (four doses of PBG, 1-8 g/kg).  Two-way ANOVA 
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for independent measures was used to compare control renal (n=38), preganglionic 
adrenal (n=32) and lumbar (n=37) sympathetic responses to four doses of PBG.  The 
effects of three doses of CGS-21680 (0.2-20 pmol) on the reflex responses of the three 
sympathetic outputs (RSNA vs. pre-ASNA vs. LSNA) at each level of activation of the 
CCR (comparisons of reflex response curves obtained after gradual activation of NTS 
A2a adenosine receptors and for changes of the reflex responses vs. control conditions, 
%) were also evaluated using two-way ANOVA for independent measures.  If 
significant interactions were found (nerve × dose), the differences between the means 
were calculated with a modified Bonferroni t-test.  One-way ANOVA for independent 
measures followed by modified Bonferroni t-test was used for comparison of HR and 
MAP reflex response curves obtained after microinjections of the three doses of 
adenosine receptor agonist, CGS-21680.  The changes in baseline levels of MAP, HR, 
RSNA, pre-ASNA and LSNA evoked by bilateral microinjections of CGS-21680 and ZM-
241385 were calculated as a difference between baseline values averaged during the 
last 30 s preceding the microinjections and the last 30 s of the 5 min period of the 
response to microinjections measured before generating the second cardiopulmonary 
chemoreflex function-curve.  An α-level of P< 0.05 was used to determine statistical 
significance.   
RESULTS 
Average resting MAP and HR values measured before the control CCR stimulus-
response curves (n=38) were: 83.5 ± 1.5 mmHg and 411.0 ± 6.1 bpm, respectively.  
Basal parameters measured just before NTS microinjections of A2a adenosine receptor 
agonist, CGS-21680, or antagonist, ZM-241385, returned to normal resting values: 82.4 
± 1.6 mmHg and 405.3 ± 6.3 bpm for MAP and HR, respectively.  Also, in those animals 
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Table 3. Changes in baseline values following A2a receptor agonist and antagonist. Baseline values of MAP, HR, 
RSNA, pre-ASNA, and LSNA following bilateral NTS microinjections of selective A2a adenosine receptor agonist, 
CGS-21680, and antagonist ZM-241385 
 
in which the third reflex curve was generated ~60 min after the microinjections 
(recovery, n=36), baseline MAP and HR were similar to those measured at the 
beginning of experiment (81.7 ± 1.2 mmHg and 398.2 ± 6.4 bpm, respectively).  There 
were no differences between these three baseline levels of MAP and HR measured 
during three stages of the experiments: control, stimulation or blockade of NTS A2a 
adenosine receptors, and recovery (P>0.05 for all comparisons).  
The effect of NTS A2a adenosine receptors on baseline values   
The effects of bilateral microinjections of the selective A2a adenosine receptor 
agonist, CGS-21680 (0.2, 2, and 20 pmol in 50 nl, n = 10, 10, and 9, respectively), and 
the selective A2a receptor antagonist, ZM-241385 (40 pmol in 100 nl, n = 9) on resting 
hemodynamic and neural variables are presented in Table 3. The effects of the smallest  
 
dose of CGS-21680 (0.2 pmol/ 50 nl) on baseline values were similar to the effects of 
bilateral microinjections of 50 nl of ACF (volume control) reported in our previous study 
(53).  Graded levels of A2a receptor activation (CGS-21680; 2, 20 pmol/ 50 nl) evoked 
similar patterns of changes in baseline levels of hemodynamic and regional sympathetic 
variables as observed previously: decreases in MAP, HR, RSNA and post-ASNA, 
increases in pre-ASNA and much smaller changes in LSNA. (104-106).  Selective 
blockade of the A2a adenosine receptors with microinjections of ZM-241385, did not 
Values are means ± SE. P < 0.05 vs. 0.2 pmol CGS; †P<0.05 vs. RSNA; ‡P<0.05 ASNA vs. LSNA; # vs. 0 
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Figure 10. An example of cardiopulmonary chemoreflex 
responses in mean arterial pressure (MAP), heart rate (HR), 
renal (RSNA), pre-adrenal (pre-ASNA) and lumbar (LSNA) 
sympathetic nerve activity evoked by intra-atrial injections of 
phenylbiguanide (1-8 g/kg) under control conditions (left 
panels) and after stimulation of the NTS A2a adenosine 
receptors (right panels) with the highest dose of the A2a agonist, 
CGS-21680 (20 pmol in 50 nl).  All recordings were performed in 
one animal.  Stimulation of the A2a receptors in the NTS virtually 
abolished the cardiopulmonary chemoreflex responses. 
alter baseline levels of any variables (P>0.05).   
Activation of NTS A2a adenosine receptors inhibits cardiopulmonary chemoreflex 
responses   
An example of original 
recordings of hemodynamic and 
neural responses to activation of the 
CCR under control and experimental 
conditions is presented in Figure 10 
(left and right panels, respectively).  
Under control conditions gradual 
activation of the cardiopulmonary 
receptors by increasing doses of PBG 
(1–8 g/kg) evoked dose-dependent 
decreases in MAP and HR and 
differential decreases in regional 
sympathetic nerve activity (RSNA > 
pre-ASNA  LSNA) (nerve effect 
P<0.0001; nerve vs. dose interaction 
P=0.007).  These differential neural 
responses were similar to those 
observed in our previous study (53).  The hemodynamic and neural reflex responses 
were powerfully inhibited following bilateral activation of NTS A2a adenosine receptors 
with the maximal dose of CGS-21680 (20 pmol/50 nl) (Figure 10, right panels).  This 
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effect was dose dependent as shown in Figure 11.   The lowest level of A2a receptor 
activation (CGS-21680, 0.2 pmol/50 nl) did not alter the control reflex responses (control 
vs. experimental condition effect P>0.05 for all variables).  Therefore this group may be 
considered as a volume control containing a physiologically insignificant amount of the 
agonist.  Increasing activation of A2a receptors (CGS-21680 2 and 20 pmol) gradually 
shifted all neural and hemodynamic reflex response curves upward and flattened them.  
At the highest dose of the agonist the inhibitory effect was highly significant (control vs. 
experimental condition effect, P<0.0001 for MAP and all the neural outputs and P=0.012 
for HR).  The slope of all reflex response function curves was significantly alerted vs. 
Figure 11. Comparisons of cardiopulmonary chemoreflex responses obtained under control conditions () vs. the 
responses obtained after microinjections of A2a receptor agonist CGS-21680, in increasing doses 0.2, 2 or 20 
pmol/ 50 nl or the selective A2a antagonist, ZM-241385, 40 pmol/ 100 nl (). Data are means ± SE. P<0.05 vs. 
control;  P<0.05 significant parallel shift of the experimental vs. control curves without significant PBG dose vs. 
experimental condition interaction. Progressive activation of A2a adenosine receptors gradually shifted the control 
reflex function upward indicating dose dependent inhibition of the reflex responses. The A2a receptor blockade 
had no effect on the reflex responses. 
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control conditions (experimental effect vs. PBG dose interactions, P<0.02 for all 
variables).   
Comparisons across the nerves (renal, pre-adrenal, and lumbar) and doses of 
CGS-21680 (0.2-20 pmol/ 50 nl) showed that the nerves responded differentially at 
each level of activation of the reflex (nerve effect, P<0.05) and were inhibited in dose-
dependent manner by A2a receptor agonist (CGS dose effect, P<0.05).  However, no 
differences were found between the inhibition of the CCR responses in RSNA, vs. pre-
ASNA, vs. LSNA; slopes of the curves were similar (no significant nerve x CGS dose 
interactions were found).  This suggests that despite the contrasting shifts in the 
baseline levels of regional sympathetic nerve activity, the stimulation of NTS A2a 
adenosine receptors similarly inhibited the reflex responses of all sympathetic outputs.  
Blockade of A2a adenosine receptors with ZM-241385, did not alter the CCR reactivity of 
all variables (far right panels of Figure 11); control vs. blockade condition effect, P>0.05 
for all variables.   
Interestingly, although stimulation of NTS adenosine A2a receptors reciprocally 
affects baseline pre-ASNA vs. post-ASNA there were no differences between the 
inhibitions of different components of the adrenal nerve.  Comparisons across pre-
ASNA, int-ASNA and post-ASNA vs. dose of CGS 21680 (0.2-20 pmol) with two-way 
ANOVA showed no nerve component effect (P>0.05 at each level of activation of the 
reflex).   
Figure 12 shows to what extent the reflex responses were inhibited after 
activation of NTS A2a adenosine receptors compared to the control reflex responses 
(% of inhibition).  A 100% inhibition corresponds to completely abolished CCR 
responses.  Downward deflections of some bars (which may represent a tendency to 
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facilitation of the reflex) were not significantly different from zero.  The regional 
sympathetic outputs were inhibited by microinjections of the A2a receptor agonist (CGS-
21680) in a dose dependent manner (highly significant dose effect P=0.002 for the 
lowest level of activation of the CCR and P<0.0001 for all higher levels of the 
activation); however, no differences between the inhibition of the sympathetic outputs 
were found (nerve effect, P>0.05 for each level of activation of the CCR).  Also the 
inhibition of all adrenal nerve components (pre-ASNA, int-ASNA and post-ASNA) was 
uniform (nerve component effect, P>0.05 for each level of activation of the CCR).  MAP 
reflex responses were also inhibited in a dose dependent manner (P<0.02) at all but the 
Figure 12. The inhibition of hemodynamic and regional sympathetic control reflex responses evoked by increasing 
doses of the A2a receptor agonist, CGS-21680 (0.2-20 pmol) at four different levels of activation of the reflex 
(phenylbiguanide 1-8 g/kg). Data are means ± SE. SNA - renal, preganglionic adrenal and lumbar sympathetic 
nerve activity. CGS-21680 exerted significant, dose dependent inhibition of the reflex responses at all levels of 
activation of the reflex.  No differences between the inhibition of the reflex responses in all regional sympathetic 
outputs were found. The negative deflections of the bars may correspond to potential facilitation of the reflex; 
however, all the negative bars were not significantly different from zero.   
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Table 4. Inhibition of the reflex responses after small dose of A2a agonist and antagonist. Cardiopulmonary 
chemoreflex responses, PBG (1-8 g/kg), after microinjections of selective A2a agonist (CGS-21680) or A2a 
antagonist (ZM-241385). 
 
Data are expressed as percent inhibition from control responses which are standardized to zero level. Positive 
values represent inhibition of the reflex while   negative numbers suggest facilitation of the responses. Values are 
means ± SE. Two-way ANOVA showed a significant drug effect (P=0.022) at moderate activation of the reflex 
(PBG, 2 g/kg) but no differences across the nerves (P>0.05 for all doses of PBG). 
 
Values are means ± SE. *P<0.05 vs. control 
 
Table 5. Averaged cardiopulmonary chemoreflex responses to PBG evoked under control conditions and 1 hour after 
microinjection of A2a adenosine receptor agonist CGS-21680. 
 
lowest level of activation of the CCR. However, the inhibition of the HR responses was 
more variable reaching significance only for the moderate activation of the CCR (4 g of 
PBG).   
Although the antagonist and the smallest dose of the agonist of A2a adenosine 
receptors had no significant effect on the CCR responses (Figure 11, the far right and 
left panels, respectively) the comparison of these two experimental conditions may 
suggest that the antagonist may show some tendency to facilitate the reflex at the 
moderate level of its activation (Table 4).  However, the drug effect reached significance 
only for regional sympathetic responses evoked by moderate activation of the CCR (2g 
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of PBG) without significant drug vs. nerve interaction. 
The A2a-mediated inhibition of the reflex responses was reversible. The CCR 
responses almost completely recovered ~60 min following NTS microinjections of A2a 
receptor agonists (Table 5).  
DISCUSSION 
 The present study showed that activation of facilitory A2a adenosine receptors in the 
NTS paradoxically inhibited CCR hemodynamic and regional sympathetic responses.  
The NTS A2a adenosine receptors stimulate neurotransmitter release so it was 
surprising that their activation inhibited the CCR.  Although stimulation of NTS A2a 
receptors evokes contrasting effects on regional sympathetic outputs (it decreases 
RSNA, increases pre-ASNA and does not markedly alter LSNA) the inhibition of the 
reflex responses of these sympathetic outputs was similar.  This study indicated that 
NTS A2a receptors are indeed present on NTS neurons/nerve terminals participating in 
CCR neurotransmission and inhibit this neurotransmission similarly as the inhibitory A1 
adenosine receptors did in our previous study (53).  Although it seems that NTS A2a 
receptors do not exert a significant, tonic inhibition of the reflex they may be activated 
upon release of adenosine into the NTS, for example during hypotensive stage of 
severe hemorrhage as we observed it previously (75; 110).  
Differential modulation of sympathoinhibitory reflexes by adenosine receptor 
subtypes 
Selective stimulation of NTS A2a adenosine receptors evokes contrasting 
changes in the baseline levels of efferent sympathetic nerve activity: decreases in 
RSNA and post-ASNA, increases in pre-ASNA, and no changes in LSNA were 
observed (104-106).  Therefore, we initially expected that activation of these receptors 
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may differentially alter CCR responses of these sympathetic outputs (it could facilitate 
RSNA reflex responses, attenuate pre-ASNA responses and less affect LSNA 
responses).  To our surprise the CCR responses of all these sympathetic outputs were 
inhibited similarly.  In addition there were no differences in A2a receptor mediated 
inhibition of different components of the adrenal nerve (pre-ASNA, int-ASNA and post-
ASNA).  This indicates that the diverse shifts in baseline levels of regional sympathetic 
nerve activity and the inhibition of CCR-evoked responses in these sympathetic outputs 
are mediated by two different, most likely independent mechanisms.  The inhibition of 
the reflex responses was probably mediated via facilitation of inhibitory mechanisms 
closely linked to the CCR pathway in the NTS, whereas contrasting shifts of baseline 
levels of regional sympathetic activity, mediated via NTS A2a adenosine receptors, seem 
independent of reflex mechanisms and glutamatergic transmission in the NTS.  We 
showed previously that these baseline shifts persist after sinoaortic denervation 
combined with vagotomy as well as after bilateral ionotropic glutamatergic blockade of 
the NTS (105; 106).  The independent effects on baseline sympathetic activity and the 
reflex sympathetic responses were similar to those observed previously where we 
assessed the modulatory effects of NTS A2a receptors on arterial baroreflex control of 
the regional sympathetic outputs (54).  In that study despite the typical contrasting shifts 
of baseline levels of pre-ASNA vs. RSNA, no resetting of the stimulus-response 
baroreflex functions along MAP axis was observed.  We proposed  that the shifts of 
baseline levels of regional sympathetic nerve activity may be mediated by A2a 
adenosine receptors located on non-glutamatergic projections to the NTS from 
hypothalamic nuclei which have dense, reciprocal connections with the NTS (for 
example, dorsomedial and paraventricular hypothalamic nuclei) (46; 96; 108). 
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Consistent with the uniform inhibition of the CCR responses in regional 
sympathetic outputs by NTS A2a adenosine receptors was also a dose dependent 
attenuation of MAP responses in this setting.  HR responses were also attenuated, 
although this effect was accompanied with much greater variability.  This variability most 
likely arises from counteracting effect of the CCR on parasympathetic and sympathetic 
control of the heart.  Although the CCR triggers powerful vagal bradycardia, this reflex 
also simultaneously activates cardiac sympathetic nerves which oppose the dominating 
parasympathetic response, as it has been shown very recently by McAllen's group (25; 
31; 95).  In addition, NTS A2a adenosine receptors may differentially affect these two 
counteracting mechanisms.  
Our previous studies showed that NTS A1 adenosine receptors inhibit 
glutamatergic transmission in the arterial baroreflex arc and in the CCR, which is 
consistent with direct inhibition of glutamate release from nerve terminals or central 
neurons by presynaptic and postsynaptic A1 receptors, respectively (53; 102; 107).  In 
contrast, activation of NTS A2a receptors did not alter arterial baroreflex responses 
however it inhibited the CCR responses similarly as A1 adenosine receptors did; 
however, via a different, likely indirect mechanism.    
Taken together, the present and previous data show that there are contrasting 
functional differences between A1 vs. A2a-adenosine receptors in neuromodulation of 
the CCR and arterial baroreflex mechanisms located in the NTS:  1) direct inhibition of 
neurotransmission in both reflex pathways is mediated by A1 receptors, 2) selective, 
indirect inhibition of CCR, but not arterial baroreflex, pathway is provided by A2a 
receptors, and 3) contrasting shifts in baseline levels of sympathetic activity mediated 
by A2a adenosine receptors are independent of the reflex mechanisms.  These 
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functional differences most likely reflect differential localization of adenosine receptor 
subtypes on NTS neurons/nerve terminals mediating both sympathoinhibitory reflexes 
and targeting different regional sympathetic outputs.  It is worth noticing that the 
differences (both functional and neuroanatomical) appear to be greater for A2a 
adenosine receptors, which dominate in the NTS, than for A1 receptors which exert 
uniform, direct inhibition of both reflexes (9; 53; 54; 102; 104-107). 
Although stimulation of NTS A2a receptors evoked powerful inhibition of the 
hemodynamic and regional sympathetic CCR responses, the blockade of these 
receptors exerted only a very small, if any, facilitation of the reflex responses indicating 
that A2a receptors do not exert a significant tonic inhibition on this reflex at the level of 
the NTS.  Lack of marked, tonic adenosine modulation of mechanisms of cardiovascular 
control at the level of the NTS and in other medullary cardiovascular centers was 
usually observed in our laboratory and by others (53; 54; 110; 123).  This is not 
surprising, as adenosine release into the NTS during normal, physiological conditions is 
negligible.  However, adenosine is released into the central nervous system, including 
the NTS, during stress/hypothalamic defense response, severe hemorrhage, ischemia 
and hypoxia (30; 87; 110; 116-118; 129; 138; 139).  During the severe hemodynamic 
imbalance adenosine levels increase several fold in the central nervous system and 
then adenosine does modulate neural control of the cardiovascular system (87; 110; 
129; 138; 139).  In the present study we used relatively small, short lasting activation of 
only one subset of receptors participating in the reflex to construct the most specific, 
dose dependent hemodynamic and regional neural stimulus-response function curves.  
Therefore the CCR depressor responses observed in the present study were too small 
and too short lasting by design to expect release of adenosine between CCR 
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stimulations.  However, in a preliminary report, we showed that during severe 
hemorrhage naturally released adenosine does inhibit neural and hemodynamic CCR 
responses and this inhibition is removed by microinjections into the NTS of nonselective 
A1/A2a adenosine receptor antagonist, 8-(p-sulfophenyl)theophylline (75).  
Potential mechanisms  
In contrast to A1 adenosine receptors which exert uniform inhibition of 
glutamatergic transmission in both CCR and arterial baroreflex pathways via decrease 
in Ca++ influx into the synaptic terminals or postsynaptic hyperpolarization of NTS 
neurons (90), the facilitory A2a receptors may exert inhibition of the CCR via more 
complex mechanisms.  The paradoxical inhibition of the CCR by A2a adenosine 
receptors may be mediated, for example, via facilitation of GABA release from NTS 
GABA-ergic neurons and/or terminals via postsynaptic and/or presynaptic A2a receptors, 
respectively.  A2a receptors may also disinhibit GABA release by removing 
dopaminergic inhibition of GABA release via direct A2a-D2 receptor interactions as it was 
suggested for basal ganglia (36; 47).  Since dopamine itself has been reported to inhibit 
afferent activation of NTS neurons (60; 61) it is also possible that A2a receptors may 
facilitate this inhibitory mechanism.  A2a receptors may also facilitate a vasoactive 
intestinal peptide dependent release of GABA as it has been shown in hippocampal 
nerve terminals (29).  Since NTS contains glycinergic terminals/receptors, given that 
glycine inhibits arterial chemoreflex at the level of the NTS in the rat, and considering 
that A2a adenosine receptors may activate glycine release from central neurons, it is 
possible that A2a adenosine receptors may inhibit the CCR via facilitation of glycine 
release which then would inhibit transmission in this reflex pathway (6; 42; 88).  It is also 
possible that adenosine A2a receptors facilitate both GABA and glycine release as co-
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localization of glycinergic and GABA-ergic mechanisms in the NTS has been reported 
(11); both GABA and glycine mediate CCR responses at the level of the rostral 
ventrolateral medulla (131).  Which of those potential mechanisms is indeed responsible 
for A2a receptor mediated inhibition of the CCR pathway remains to be elucidated in 
future studies. 
Limitation of the method 
Major limitations of the method were described in detail in our previous study 
concerning NTS A1 adenosine receptor mediated inhibition of the CCR (53).  Briefly, we 
believe that this method of evoking the CCR with increasing doses of PBG, which 
activate only a subset of CCR afferents, is a good, well controlled experimental tool 
widely accepted in the field (19; 38; 40; 52; 57; 95; 100; 101; 130).  Selective activation 
of serotonin 5HT3 receptors on polymodal vagal afferents from cardiopulmonary area 
dissects the activation of CCR from other reflexes and humoral mechanisms which may 
be triggered by cardiac ischemia which is known to naturally activate the CCR (17; 50; 
67; 83; 93; 97).  Although we could not distinguish between adrenal nerve fibers 
supplying adrenergic vs. noradrenergic chromafin cells in the adrenal medulla it has 
been shown previously that both these types of adrenal nerve fibers are similarly 
inhibited by activation of the CCR (19). 
In the present paper we did not provide the microinjection volume control for the 
hemodynamic and regional neural responses evoked by the CCR.  However, this 
volume control was completed in our previous study and did not show any effects on the 
hemodynamic and regional neural reflex responses evoked by activation of the CCR 
and the arterial baroreflex (53; 54; 102).  In addition, the lowest dose of A2a receptor 
agonist (CGS-21680, 0.2 pmol) did not alter the reflex reactivity in all recorded 
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variables; therefore it may serve well as a volume control containing physiologically 
negligible amount of the agonist.   
Perspectives and significance 
We reported previously that activation of adenosine A1 receptors inhibits 
glutamatergic transmission in arterial baroreflex and CCR pathways at the level of the 
NTS (53; 102; 107).  These studies suggested that adenosine, operating via inhibitory 
A1 receptors, may attenuate hypotension mediated by sympathoinhibitory reflexes, 
which are primarily integrated in the NTS.  This mechanism may contribute to fine 
tuning of these reflexes in preventing excessive depressor and consequently ischemic 
effects.  The present study showed that activation of facilitatory A2a receptors in the NTS 
paradoxically inhibits CCR control of regional sympathetic outputs although it does not 
inhibit baroreflex control of these outputs (54).  This indicates that both A1 and A2a 
adenosine receptor subtypes act in concert by powerfully inhibiting the CCR; however, 
via two different mechanisms:  direct and indirect inhibition of neurotransmission in this 
reflex arc mediated by A1 and A2a receptors, respectively.  The inhibitory effects of NTS 
A2a receptors were nearly as powerful as those exerted by NTS A1 receptors (53).  This 
shows that adenosinergic inhibition of the CCR at the level of the NTS is much more 
potent than the inhibition of baroreflex pathway which is mediated only by NTS A1 
adenosine receptor subtype.  This difference may have a physiologic basis because the 
cardiopulmonary chemoreflex (or Bezold-Jarisch reflex) may cause more severe 
bradycardia and hypotension than that normally evoked by activation of the arterial 
baroreflex.  Therefore, the CCR needs a stronger negative feedback system compared 
to the arterial baroreflex.  Powerful activation of the depressor Bezold-Jarisch reflex 
may lead to severe hemodynamic imbalance, ischemia and consequently to the release 
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of adenosine into the NTS.  Then, adenosine may act as especially powerful negative 
feedback regulator for this reflex, via both A1 and A2a adenosine receptor subtypes.  The 
above mechanism may prevent potentially dangerous consequences, for example, 
fainting or life threatening bradyarrhythmias, arising from simultaneous activation of 
vagal and sympathetic control of the heart, which may lead even to sudden cardiac 
death of young athletes (13; 48; 68; 95). 
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CHAPTER 3 
NTS A2a adenosine receptors inhibit the cardiopulmonary chemoreflex control of 
regional sympathetic outputs via GABA-ergic mechanism 
ABSTRACT 
Adenosine is a powerful central neuromodulator acting via opposite A1 
(inhibitory) and A2a (excitatory) receptors.  However, in the NTS both adenosine 
receptor subtypes attenuate cardiopulmonary chemoreflex (CCR) sympatho-inhibition of 
renal, adrenal and lumbar sympathetic nerve activity and reflex decreases in arterial 
pressure and heart rate.  A1 receptors inhibit glutamatergic transmission in the CCR 
pathway whereas A2a receptors most likely facilitate release of an unknown inhibitory 
neurotransmitter which in turn inhibits the CCR.  We hypothesized that A2a adenosine 
receptors inhibit the CCR via facilitation of GABA release in the NTS.  In 
urethane/chloralose anesthetized rats (n=51) we compared regional sympathetic 
responses evoked by stimulation of the CCR with right atrial injections of serotonin 5HT3 
receptor agonist, phenylbiguanide, (PBG 1-8 g/kg) before and after selective 
stimulation of NTS A2a adenosine receptors (microinjections into the NTS of CGS-21680 
20 pmol/50 nl) preceded by blockade of GABAA or GABAB receptors in the NTS 
(bicuculline 10 pmol /100 nl, or SCH-50911, 1 nmol/100 nl).  We found that stimulation 
of NTS A2a adenosine receptors inhibits CCR evoked hemodynamic and regional 
sympathetic reflex responses via a GABA-ergic mechanism.  Blockade of GABAA 
receptors virtually abolished A2a mediated inhibition of the CCR and had tonic effects on 
the reflex mechanism.  GABAB receptors had much weaker but significant effects.  
These effects were similar for the different sympathetic outputs.  We conclude that 
adenosine operating in the NTS inhibits CCR integration by both A1 and A2a receptor 
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subtypes, although via very different mechanisms: direct inhibition of glutamate release 
and facilitation of GABA release, respectively. 
INTRODUCTION 
Adenosine modulates cardiovascular reflexes primarily integrated in the nucleus 
of the solitary tract via inhibitory A1 receptors and facilitory A2a receptors linked to Gi 
and Gs proteins, respectively (1; 16; 81; 90; 103; 108; 115; 123).  Activation of 
adenosine A1 and A2a receptors inhibits and facilitates neurotransmitter release and 
central neurons via pre- and postsynaptic mechanisms, respectively.  Under 
physiological conditions a natural source of adenosine in the NTS is ATP released from 
nerve terminals and glial cells and then catabolized by ectonucleotidases; this 
mechanism may be triggered by stress/hypothalamic defense response (30; 116-118; 
142).  Under pathological conditions such as ischemia, hypoxia and severe hemorrhage 
intracellular ATP is catabolized to adenosine and adenosine is globally released from 
hypoxic neurons and glial cells (87; 129; 138; 138; 139).  Therefore adenosine acts 
spatially reaching both A1 and A2a receptors in NTS neuronal network.  However, this 
neuromodulator produces specific patterns of autonomic responses most likely due to 
the differential location of these two antagonistic receptors on NTS neurons/terminals 
which participate in different reflexes and finally target different sympathetic outputs (98; 
103; 104; 107; 108).  Selective activation of NTS A1 and A2a receptors usually, but not 
always yields reciprocal results.  For example, activation of A2a receptors results in 
depressor responses accompanied with contrasting regional sympathetic responses: 
decreases in renal (RSNA), increases in preganglionic adrenal (pre-ASNA) and no 
changes in lumbar (LSNA) sympathetic nerve activity (98; 104).  In contrast, selective 
activation of NTS A1 adenosine receptors evokes mostly pressor responses 
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accompanied with differential increases in regional sympathetic activity (pre-
ASNA>RSNA≥LSNA) (107).  Selective stimulation of NTS A1 and A2a receptors has also 
different effects on integration of baroreflex control of regional sympathetic outputs: A1 
receptors inhibit glutamatergic transmission which uniformly shifts the baroreflex 
stimulus response functions for RSNA, pre-ASNA and LSNA toward higher mean 
arterial pressure (MAP) (102; 107); in contrast A2a receptors do not alter the baroreflex 
set point although they decrease baseline level of neural activity as well as the gain and 
range of the reflex for RSNA and increase all these variables for pre-ASNA via non-
baroreflex mechanisms (54). 
These two antagonistic receptors may also act in concert to inhibit the 
cardiopulmonary chemoreflex (CCR) control of regional sympathetic outputs acting via 
different mechanisms within the NTS.  The CCR, also known as Bezold-Jarisch reflex, 
is triggered by polymodal mechano- and chemoreceptors and mediated by afferent 
vagal C fibers (26; 84; 85; 97; 124-126).  This reflex evokes profound depressor, 
cardiac slowing and sympathoinhibitory responses which can lead to fainting and has 
been occasionally attributed to sudden cardiac death in young athletes (13; 68; 97).  
Inasmuch as activation of A1 receptors inhibits neurotransmitter release, these 
receptors likely inhibit the CCR within the NTS by inhibiting glutamatergic transmission 
in the CCR pathway similarly as occurs in the arterial baroreflex network (53).  In 
contrast, the facilitatory A2a receptors may inhibit the CCR reflex pathway via release of 
an inhibitory neurotransmitter (78).  The most likely candidate is GABA as stimulation of 
central A2a adenosine receptors does facilitate GABA release in different neuronal 
networks including respiratory reflexes integrated in the NTS (2; 28; 36; 41; 47; 69; 70; 
86; 113; 137).  Negative GABA-ergic feedback operating at the level of the NTS in 
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arterial baro- and chemoreflex pathways is well documented (55; 56; 65; 74; 119; 120; 
128; 133; 140; 141).  There is extensive evidence that both GABAA and GABAB 
receptors operate synergistically inhibiting these reflexes at the level of the NTS (55; 
120; 128; 140; 141).  Both GABAA and GABAB receptors are tonically active in 
modulation of the baroreflex network at the level of the NTS (55; 119; 141).  It is 
unknown if GABA-ergic negative feedback also operates in the CCR pathway although 
Zhang and Mifflin speculated that GABA may be involved in the regulation of all 
cardiovascular reflexes integrated in the NTS (141).  Therefore, since activation of A2a 
receptors in the NTS inhibits the CCR and these receptors facilitate neurotransmitter 
release, we hypothesize that these receptors facilitate GABA release which thereby 
inhibits CCR control of regional sympathetic outputs.  The present study was designed 
to answer the following specific questions:  1) Do NTS A2a adenosine receptors inhibit 
the CCR control of regional sympathetic outputs via facilitation of GABA release in the 
NTS network?  2) Are both GABAA and GABAB receptors involved?  3) Does GABA 
tonically inhibit the CCR pathway under normal conditions? 
METHODS 
All protocols and surgical procedures employed in this study were reviewed and 
approved by the Institutional Animal Care and Use Committee and were performed in 
accordance with the Guide for the Care and Use of Laboratory Animals endorsed by the 
American Physiological Society and published by the National  Institutes of Health.  
Design 
 The experiments were performed using 51 male Sprague-Dawley rats, weighing 
373.5 g (mean ± SE = 373.5 ± 6.9 g).  In 27 rats the contribution of GABA-ergic 
mechanisms to A2a adenosine receptor mediated inhibition of cardiopulmonary 
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chemoreflex responses of regional neural and hemodynamic variables was assessed; 
CCR stimulus response function curves  obtained under control conditions were 
compared with the curves obtained after bilateral microinjections into the NTS of A2a 
adenosine receptor agonist (CGS-21680, 20 pmol/50 nl) following pretreatment with: 
vehicle control (microinjections of 100 nl artificial cerebrospinal fluid, ACF) or blockade 
of NTS GABAA or GABAB receptors (microinjections of Bicuculline, 10 pmol/100 nl, or 
SCH-50911, 1 nmol/100 nl, respectively).  To asses potential tonic effects of NTS 
GABA-ergic mechanisms on CCR control of regional neural and hemodynamic 
variables, in 24 rats the CCR function curves were compared before and after the 
GABAA or GABAB receptor blockade alone.  CCR reactivity was also assessed 
approximately one hour after the pharmacological manipulation in the NTS (recovery).  
The timeline of the protocol is presented in Figure 13. 
Instrumentation and measurements   
All procedures were described in detail previously (53; 100; 105-107).  Briefly, 
Figure 13. Timeline of experiments. Small arrows indicate bolus injections of phenylbiguanide (PBG) in increasing 
doses (1-8 g/kg) into the right atrium in ~2.5 min intervals. Double large arrows represent bilateral microinjections 
into the NTS of: a) artificial cerebrospinal fluid, ACF (100 nl) or GABAA receptor antagonist, Bicuculline (10 pmol/ 
100 nl) or GABAB receptor antagonist, SCH-5011 (1 nmol/100 nl) followed by A2a adenosine receptor agonist CGS-
21680 (20 pmol in 50 nl), or b) GABAA receptors antagonist alone (Bicuculline 10 pmol/ 100 nl) or GABAB receptors 
antagonist alone (SCH-5011 1 nmol/ 100 nl).  
 
69 
 
male Sprague-Dawley rats (Charles River) were anesthetized with a mixture of α-
chloralose (80 mg·kg-1) and urethane (500 mg·kg-1 i.p.), tracheotomized, connected to a 
small-animal respirator (SAR-830, CWE, Ardmore, PA), and artificially ventilated with 
40% oxygen, 60% nitrogen mixture.  Arterial blood gases were tested occasionally 
(Radiometer, ABL500, OSM3), and ventilation was adjusted to maintain Po2, Pco2, and 
pH within normal ranges.  Average values measured at the end of each experiment 
were: Po2 = 156.8 ± 6.2 Torr, Pco2 = 34.3 ± 0.8 Torr and pH = 7.41 ± 0.0.  The left 
femoral artery and vein were catheterized to monitor arterial blood pressure; infuse 
drugs and to supplement anesthesia (12–21 mg·kg-1·h-1 of α-chloralose and 76–133 
mg·kg-1·h-1 of urethane dissolved in 2.4–4.2 ml·kg-1·h-1 saline), respectively.  An 
additional catheter was inserted via the right jugular vein for PBG injections into the right 
atrium.   The appropriate position of the catheter in the right atrium was confirmed post 
mortem.  Sinoaortic denervation was performed and tested similarly as in the previous 
studies from our laboratory; special attention was given to preserve the vagus nerve 
(53; 100; 105; 107).  
Neural recording 
In each experiment, simultaneous recordings from three (n=41) or two 
sympathetic outputs (n=10) were performed.  Renal and adrenal nerves were exposed 
retroperitoneally form a flank incision, whereas lumbar sympathetic trunk was exposed 
from midabdominal incision.  Neural recordings were accomplished as described 
previously (53; 100; 105-107).  Neural signals were initially amplified (2,000–20,000×) 
with bandwidth set at 100–1,000 Hz, digitized, rectified, and averaged in 1-s intervals.  
Background noise was determined after the animal was euthanized yet artificially 
ventilated to leave unaltered any potential movement artifacts.  Resting level of the 
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nerve activity was normalized to 100% before each activation of the CCR. 
The ratio between preganglionic and total nerve activity was initially tested with 
an intravenous bolus injection of the short-lasting (1-2 min) ganglionic blocker, Arfonad 
(trimethaphan, 2 mg·kg-1; Hoffmann-La Roche), and finally evaluated at the end of each 
experiment with hexamethonium (20 mg·kg-1 i.v.).  RSNA was virtually completely 
postganglionic; 7.3 ± 2.4% (n = 48) of the activity persisted after the ganglionic 
blockade; LSNA was mostly postganglionic; 34.9 ± 4.3% (n = 51) of preganglionic 
activity remained after the blockade.  Total of 43 adrenal nerves were recorded with 28 
being predominantly preganglionic pre-ASNA (>75% of activity remained after the 
ganglionic blockade), 7 were predominantly postganglionic post-ASNA (<50% of activity 
remained after the ganglionic blockade) and 8 had intermediate composition, int-ASNA 
(50%-75% of activity remained after the ganglionic blockade).  Average levels of 
preganglionic, intermediate, and postganglionic adrenal nerve activity after ganglionic 
blockade were: 90.2 ± 2.2, 62.4 ± 3.0, 34.7 ± 7.3%, respectively.  Stimulation of the 
CCR similarly inhibits all three components of the adrenal nerve, although this inhibition 
is significantly different than the inhibition of RSNA and LSNA (RSNA>ASNA>LSNA) 
(53; 78).  Also activation of A2a adenosine receptors similarly inhibits all three 
components of the adrenal nerve (78).  Therefore, in the present study all components 
of the adrenal nerve were combined for further analysis and referred as ASNA (n=43).  
The arterial pressure and neural signals were digitized and recorded with a 
Hemodynamic and Neural Data Analyzer (Biotech Products, Greenwood, IN), averaged 
over 1-s intervals, and stored on the hard disk for subsequent analysis. 
Microinjections into the NTS  
Bilateral microinjections of the volume control (ACF, 100 nl), GABAA or GABAB 
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Figure 14. The microinjection sites for all experiments were located within 
subpostremal nucleus tractus solitarii (NTS) as shown in schematic 
diagrams of transverse sections of the medulla oblongata from a rat brain. 
AP, area postrema; c, central canal; 10, dorsal motor nucleus of vagus 
nerve; 12, nucleus of hypoglossal nerve; Ts, tractus solitarius; Gr, gracile 
nucleus; Cu, cuneate nucleus.  Scale is shown at the bottom; number on 
the left of schematic diagram denotes the rostrocaudal position in 
millimeters of the section relative to the obex according to the atlas of the 
rat subpostremal NTS by Barraco et al. (7).  Bilateral microinjection sites 
for different pharmacological agents were marked with fluorescent dye. A: 
, ACF (100 nl)+CGS-21680(20 pmol/50 nl); , Bicuculline (10 pmol/ 100 
nl)+CGS-21680 (20 pmol/50 nl);   SCH-50911 (1 nmol/ 100 nl)+CGS-
21680 (20 pmol/ 50 nl)   B: , Bicuculline (10 pmol/ 100 nl); , SCH 
50911 (1 nmol/ 100 nl).  
receptor blockade (Bicuculline, 10 pmol/ 100 nl or SCH-50911, 1 nmol/ 100 nl, 
respectively) followed ~2-3 min later with selective A2a receptor agonist, CGS-21680 (20 
pmol in 50 nl of ACF) were made with multibarrel glass micropipettes into the medial 
region of the caudal NTS as 
described previously (9; 53; 
105; 107).  The doses and 
volumes of the agonist and 
antagonist were the same as 
used in previous studies (53; 
54; 55; 102; 106; 107; 110; 
133).  The drugs were 
dissolved in ACF with pH 
adjusted to 7.2 since the 
selective A2a adenosine 
receptor agonist CGS-
21680 often precipitates in a 
pH >7.2.  All microinjection 
sites were marked with DiI 
lypophilic dye (Molecular 
Probes, CA) and verified histologically as described previously (9; 53; 105; 107).  The 
microinjection sites are presented in Figure 14 using diagrams based on the atlas of the 
rat subpostremal NTS by Barraco et al. (7). 
Cardiopulmonary chemoreflex stimulus-response curves 
The cardiopulmonary receptors were stimulated using bolus injections into the 
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right atrium of increasing doses (1-8 g/kg) of serotonin 5HT3 receptor agonist, 
phenylbiguanide (PBG, Sigma, 20 g/1 ml solution in 0.9% NaCl) in 2.5 min intervals 
between the injections (53; 100; 101).  Total time to complete the stimulus-response 
curve was ~ 8 min.  The curves obtained under control conditions were compared with 
those obtained 30 min later, approximately 2.5 min after bilateral microinjections of 
pharmacological agents into the caudal NTS (either ACF 100 nl or Bicuculline 10 
pmol/100 nl or SCH-50911 1 nmol/ 100 nl followed with CGS-21680 20 pmol/50 nl, or 
Bicuculline 10 pmol/100 nl or SCH-50911 1 nmol/ 100 nl alone) and again with curves 
obtained 60 min after the microinjections, recovery (Figure 13).   This approach allowed 
assessment of the CCR reactivity during the most effective action of the adenosine A2a 
receptor activation which occurs ~ 5-15 min after the microinjection of the agonist (CGS-
21680) (105; 106). 
Data analysis 
 The cardiopulmonary reflex stimulus-response curves constructed for MAP, HR, 
RSNA, ASNA and LSNA under control conditions were compared with those generated 
after bilateral stimulation of NTS A2a adenosine receptors (CGS-21680, 20 pmol/ 50 nl) 
preceded by either volume control (ACF, 100 nl) or, GABAA (bicuculline, 10 pmol/ 100 
nl) or GABAB (SCH-50911, 1 nmol/ 100 nl) receptors blockade.  The CCR function 
curves were also compared before and after blockade of either GABAA or GABAB 
receptors alone.  Additionally, the control CCR stimulus-response curves were 
compared with those generated ~60 min after the microinjections (recovery).  The 
maximal reflex responses in all measured variables were compared between the 
experimental conditions: ACF+CGS-2160 vs. Bicuculline+CGS-21680 or SCH-
50911+CGS-21680 and bicuculline alone vs. SCH-50911 alone.  The effects exerted by 
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activation of A2a receptors preceded by volume control or GABA-ergic blockade on the 
reflex responses were calculated according to the equation: [(control response - 
response after the microinjection into the NTS)/control response] x 100%.  100% 
inhibition reflects completely abolished CCR response, whereas negative values 
represent facilitation of the reflex.  The same equation was used to calculate the effects 
of blockade of GABAA or GABAB receptors alone on the reflex responses. 
The data were analyzed using the statistical package SYSTAT version 11 
(SYSTAT Software Inc., Richmond, CA, USA).  Two-way ANOVA for repeated 
measures was used to compare the reflex responses of each variable across the 
experimental conditions (control vs. microinjection and control vs. recovery) and across 
four levels of activation of the CCR (four doses of PBG, 1-8 g/kg).  Two-way ANOVA 
for independent measures was used to compare control renal (n=48), adrenal (n=43) 
and lumbar (n=51) sympathetic CCR responses to four doses of PBG (1-8 g/kg).  Two-
way ANOVA for independent measures was used to analyze the relative changes in 
reactivity for:  ACF+CGS-2160 vs. Bicuculline+CGS-21680 and ACF+CGS-2160 vs. 
SCH-50911+CGS-21680.  Two-way ANOVA for independent measures was also used 
for comparisons of relative changes in the reflex responses of three sympathetic outputs 
(RSNA vs. ASNA vs. LSNA)  evoked  by GABAA vs. GABAB receptor blockades (NTS 
microinjections of Bicuculline, 10 pmol/100 nl, vs. SCH-50911, 1 nmol/ 100 nl, 
respectively) at each level of activation of the CCR (PBG 1-8 g).  If significant 
interactions (nerve × drug) were found, the differences between the means were 
calculated with a modified Bonferroni t-test.  One-way ANOVA for independent 
measures followed by modified Bonferroni t-test was used for comparison of HR and 
MAP reflex response curves.  The changes in baseline levels of MAP, HR, RSNA, 
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ASNA and LSNA evoked by bilateral microinjections of either ACF or Bicuculline or 
SCH-50911 followed by CGS-21680 or effects of microinjections of Bicuculline or SCH-
50911 alone were calculated as a difference between baseline values averaged during 
the last 30 s preceding the microinjections and the last 30 s of the 2.5 min period of the 
response to microinjections measured before generating the second cardiopulmonary 
chemoreflex function-curve.  An α-level of P< 0.05 was used to determine statistical 
significance. 
RESULTS 
Average baseline MAP and HR values measured before the control CCR 
stimulus-response curves (n=51) were: 84.8 ± 1.4 mmHg and 398.9 ± 7.2 bpm, 
respectively.  The baseline values measured just before NTS microinjections of drugs 
into the NTS returned to control levels: 82.6 ± 1.5 mmHg and 398.2 ± 4.6 bpm for MAP 
and HR, respectively.  Also, baseline MAP and HR values measured ~60 min after the 
microinjections (recovery, n=51), were not markedly different from those measured at 
the beginning of experiment (79.4 ± 1.5 mmHg and 379.1 ± 7.4 bpm, respectively). 
Effects of GABA-ergic blockade on NTS A2a adenosine receptor mediated 
changes in baseline values 
The effects of bilateral microinjections of the selective A2a adenosine receptor 
agonist, CGS-21680 (20 pmol in 50 nl) following volume control (ACF, 100 nl, n=7), 
GABAA receptors blockade (Bicuculline, 10 pmol/ 100 nl, n=13), or GABAB receptors 
blockade (SCH-50911, 1 nmol/ 100 nl, n=7) on resting hemodynamic and neural 
variables are presented in Table 6. Selective activation of A2a adenosine receptors 
following volume control evoked a typical pattern of changes in baseline levels of 
hemodynamic and regional sympathetic variables as observed in our previous studies  
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Table 6. Changes in baseline values under different experimental conditions. Values of MAP, HR, RSNA, ASNA, 
and LSNA after bilateral NTS microinjections of selective A2a adenosine receptor agonist CGS-21680, following 
respective volume control (ACF), GABAA blockade (Bicuculline) or GABAB receptors blockade (SCH-50911) 
 
Values are means ± SE. *P < 0.05 vs. ACF 100 nl + CGS-21680 (20 pmol/ 50 nl); †P<0.05 vs. RSNA; ‡P<0.05 
ASNA vs. LSNA. 
 
Table 7. Changes in baseline values following GABA-erigc blockade.  Values of MAP, HR, RSNA, ASNA, and 
LSNA following bilateral NTS microinjections of Bicuculline or SCH-50911 receptors blockade  
 
Values are means ± SE. *P < 0.05 vs. SCH-50911; †P<0.05 vs. RSNA; ‡P<0.05 ASNA vs. LSNA. 
 
during activation of A2a receptors alone: decreases in MAP, HR, and RSNA, increases in 
ASNA and much smaller changes in LSNA.  Pretreatment with GABAA receptor 
antagonist attenuated A2a receptor mediated decreases in MAP and tended to 
decrease changes in all other baseline values; however this effect did not reach 
statistical significance.  Pretreatment with GABAB receptor antagonist did not 
significantly change A2a receptor-evoked alterations in baseline values although it 
tended to reverse the responses in baseline ASNA.  Blockade of GABAA and GABAB 
receptors alone did not markedly affect the baseline values although it tended to decrease 
them slightly (Table 7). 
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Figure 15. An example of cardiopulmonary chemoreflex responses in mean arterial pressure (MAP), heart rate 
(HR), renal (RSNA), adrenal (ASNA) and lumbar (LSNA) sympathetic nerve activity evoked by intra-atrial injections 
of phenylbiguanide (1-8 g/kg) under control conditions (left panels), and after stimulation of the NTS A2a adenosine 
receptors preceded by volume control (CGS-21680 20 pmol/ 50 nl+ACF 100 nl, middle panels) or following 
stimulation of the A2a adenosine receptors preceded by GABAA receptor blockade (Bicuculline, 10 pmol/ 100 nl + 
CGS-21680, 20 pmol/ 50 nl, in left panels).  The left and right panels are recordings preformed in one animal while 
the middle panels show powerful inhibition of the CCR responses following activation of A2a receptors recorded in 
the other animal (ACF + CGS-21680). GABAA receptor blockade markedly attenuated A2a mediated inhibition of the 
CCR responses. 
 
The effects of GABA-ergic blockade on NTS A2a adenosine receptor mediated 
inhibition of cardiopulmonary chemoreflex responses   
An example of original recordings and the averaged data for hemodynamic and 
neural responses evoked by activation of the CCR under control and experimental 
conditions are presented in Figures 15 and 16.  Under control conditions (Figure 15, left 
panels, Figure 16 solid lines) gradual activation of the cardiopulmonary receptors by 
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increasing doses of  PBG (1-8 g/kg) evoked dose-dependent decreases in MAP and 
HR and uniform, yet differential inhibition in regional sympathetic nerve activity (RSNA > 
ASNA > LSNA) similarly as previously observed (53).  Two-way ANOVA for all control 
data and all levels of the reflex activation showed a significant nerve effect (p < 0.0001) 
and nerve vs. dose interaction (p = 0.001).  Bilateral activation of NTS A2a adenosine 
receptors following pretreatment with volume control powerfully inhibited the CCR 
hemodynamic and neural reflex responses (Figure 15, middle panels, Figure 16 left 
panels).  This inhibition was similar to that observed previously when NTS A2a 
adenosine receptors were activated without pretreatment with ACF (78).  Blockade of 
NTS GABAA receptors abolished the inhibitory effect of adenosine A2a receptor 
stimulation on the CCR (Figure 15, right panels, Figure 16, middle panels).  Two-way 
ANOVA showed no significant differences between the experimental conditions for all 
comparisons; however, slopes for HR and RSNA remained slightly altered after the 
blockade (experimental condition vs. dose interactions were significant for these two 
variables, P<0.05).  The blockade of GABAB receptors decreased NTS A2a receptor-
mediated inhibition of the CCR responses to a lesser extent.  The difference between 
control and experimental reflex function curves was smaller after GABAB receptor 
blockade (Figure 16, right panels) compared to the effect of volume control (Figure 16, 
left panels).  However, some of A2a receptor mediated inhibition of the reflex responses 
persisted after GABAB blockade; two-way ANOVA showed significant experimental 
condition effects (P<0.05) for all variables except for HR (Figure 16, right panels). 
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Figure 16. Comparisons of cardiopulmonary chemoreflex responses obtained under control conditions () vs. the 
responses obtained after microinjections of either volume control (ACF, 100 nl), GABAA (Bicuculline 10 pmol/ 100 nl), 
or GABAB (SCH 50911, 1 nmol/ 100 nl), receptors antagonists followed by A2a receptor agonist (CGS-21680, 20 pmol/ 
50 nl), (). Data are means ± SE. P<0.05 vs. control;  P<0.05 significant parallel shift of the experimental vs. 
control curves without significant PBG dose vs. experimental condition interaction.  Activation of A2a receptors 
following volume control showed powerful inhibition of the hemodynamic and regional sympathetic CCR responses.  
GABAA receptor blockade attenuated adenosine A2a receptor mediated inhibition of the CCR responses, while GABAB 
receptors had smaller effect.  
  
 
Figure 17 shows the extent of A2a mediated-inhibition of the CCR reflex 
responses under each experimental condition (pretreatment with volume control vs. 
GABAA or GABAB receptor blockade).  A 100% inhibition corresponds to a  completely  
abolished reflex response, while 0% change represents no inhibition of the reflex 
reactivity. Selective activation of A2a receptors following volume control (ACF) markedly 
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Figure 17. The relative inhibition of hemodynamic and regional sympathetic reflex evoked by stimulation of NTS A2a 
adenosine receptors (CGS-21680, 20 pmol/ 50 nl) after pretreatment with volume control (ACF+CGS), GABAA 
receptor blockade (microinjections of Bicuculline, 10 pmol/ 100 nl, BIC+CGS) or GABAB receptor blockade 
(microinjections of SCH-50911, 1 nmol/100 nl, SCH+CGS) at four different levels of activation of the reflex 
(phenylbiguanide, PBG 1-8 g/kg). Data are means ± SE. SNA - sympathetic nerve activity (renal, adrenal and 
lumbar). GABAA receptor blockade removed A2a receptor mediated inhibition of reflex responses to much greater 
extent than GABAB receptor blockade. 
 
inhibited the CCR responses.  This inhibition was virtually abolished by NTS GABAA 
blockade; the remaining inhibition was not different from zero for HR and all neural 
responses except for RSNA at 4 g of PBG.  In contrast, after GABAB receptor blockade 
the inhibition of reflex responses tended to decrease but A2a receptor activation still 
caused significant attenuation of the CCR responses.  Two-way ANOVA showed 
significant ACF vs. GABAA blockade effect (P<0.05 for all levels of activation of the 
reflex) without significant nerve effects and experimental condition vs. nerve 
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Table 8.  Averaged cardiopulmonary chemoreflex responses to PBG (1-8 g/kg) evoked under control conditions 
(control) and 1 hour after microinjection of drugs (recovery). 
 
Values are means ± SE. PBG, phenylbiguanide; HR, heart rate, MAP, mean arterial pressure, RSNA, renal 
sympathetic nerve activity, ASNA, adrenal sympathetic nerve activity; LSNA, lumbar sympathetic nerve activity.  
 
interactions.  This showed that following GABAA blockade all nerve responses were 
similarly restored towards control levels.  The GABAB blockade had a much smaller 
effect.  Two-way ANOVA showed a significant ACF vs. GABAB blockade effect only for 
moderate activation of the reflex (PBG 2 and 4 g). 
The reflex reactivity returned to normal levels ~ 60 min after GABA receptor 
blockade.  No significant differences between the experimental conditions were found 
for neural and hemodynamic variables (Table 8). 
 
Figure 18 shows effects of NTS GABA-ergic blockade alone on the CCR 
responses.  Blockade of GABAA receptors in the NTS tended to exaggerate the reflex  
responses (Figure 18, left panels).  However, differences between control and 
experimental reflex function curves did not reach statistical significance.  Nevertheless, 
when more specific comparisons of changes in reflex reactivity were measured at each 
level of activation of the reflex they revealed facilitation of the reflex (Figure 19).  Figure 
19 shows ∆% change of the reflex responses obtained after GABAA and GABAB 
blockade compared to the respective control responses.  Data were computed similarly 
as in Figure 17; upward deflections represent inhibition and downward deflections 
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represent facilitation of the reflex responses.  The blockade of GABAA receptors 
significantly facilitated CCR reflex responses of all neural and hemodynamic variables 
at   moderate levels   of CCR  activation  (PBG, 2  and  4 g/kg).  In contrast, GABAB  
receptor blockade did not alter the reflex reactivity (virtually no significant differences vs. 
zero were found).  Two-way ANOVA confirmed significant drug effect (Bicuculline vs. 
SCH-50911, P<0.05 for all variables at all levels of activation of the reflex).  These data 
suggest that endogenous GABA operating mostly via GABAA receptors may provide 
some tonic inhibition of the CCR pathway at the level of the NTS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
                                       
 
Figure 18. Comparisons of cardiopulmonary chemoreflex 
responses obtained under control conditions () vs. the 
responses obtained NTS GABAA or GABAB receptor blockades 
(microinjections of Bicuculline, 10 pmol/ 100 nl or SCH-50911, 1 
nmol/100 nl, respectively) ().  Data are means ± SE. GABAA 
receptor blockade tended to facilitate the reflex responses 
(downward shifts of the reflex function curves obtained after the 
blockade). 
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DISCUSSION  
  The present study revealed the mechanism by which A2a adenosine receptors 
exert powerful inhibition of hemodynamic and regional sympathetic CCR responses.  In 
contrast to A1 adenosine receptors, which directly inhibit glutamatergic transmission in 
arterial baro- and cardiopulmonary chemoreflex pathways (53; 102; 107), A2a receptors 
facilitate release of GABA which in turn inhibits the CCR network.  Although A2a 
adenosine receptors do not inhibit the arterial baroreflex pathway (54) they provide 
powerful GABA-ergic inhibition of the CCR.  This GABA-ergic inhibition is mediated 
mostly via GABAA receptors with a much smaller contribution of GABAB receptors.  The 
Figure 19. The relative changes of hemodynamic and regional sympathetic reflex responses evoked by GABAA 
or GABAB receptor blockade in the NTS (microinjections of Bicuculline, 10 pmol/ 100 nl, or SCH-50911, 1 
nmol/100 nl, respectively) at four different levels of activation of the cardiopulmonary chemoreflex (intra-atrial 
phenylbiguanide, PBG 1-8 g/kg). Data are means ± SE. SNA, sympathetic nerve activity (renal, adrenal and 
lumbar). The negative deflections of the bars correspond to facilitation of the reflex in comparison to respective 
control conditions. GABAA receptor blockade facilitated the reflex responses; the relative changes in reactivity 
were significantly different from zero, especially for moderate activation of the reflex. 
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inhibition of the reflex responses was similar for different regional sympathetic outputs 
despite the marked regional differences in response to stimulation of NTS A2a 
adenosine receptors themselves as well as the responses to the CCR.  Importantly, the 
present study showed for the first time that GABA-ergic feedback operates in the CCR 
mechanisms at the level of the NTS and provides slight, although significant, tonic 
inhibition of the reflex.  
A2a adenosine receptor mediated GABA-ergic inhibition of the CCR 
Adenosine A2a receptor–mediated facilitation of GABA release has been shown 
in the cerebral cortex, basal ganglia, and hippocampus (2; 28; 36; 41; 47; 69; 70; 86; 
113; 137).  Further, A2a adenosine receptor mediated facilitation of GABA release in 
medullary respiratory centers has been reported as injections of A2a receptor agonist 
CGS-21680 into the fourth ventricle of piglets and rats inhibited respiratory drive and 
this effect was abolished by bicuculline (69; 137).  Also apnea evoked by stimulation of 
the superior laryngeal nerve in piglets was facilitated by A2a adenosine receptor 
stimulation and this inhibition was removed by bicuculline (2).  In contrast, selective 
stimulation of NTS A2a adenosine receptors does not inhibit arterial baroreflex control of 
HR and regional sympathetic outputs (54), although presence of GABA-ergic negative 
feedback is well documented in this reflex pathway (55; 56; 65; 74; 119; 120; 128; 133; 
140; 141).  NTS A2a receptors do modulate baroreflex control of regional sympathetic 
outputs; however, only via reciprocal alterations of the baseline levels of renal vs. 
adrenal nerve activity which occur via non-baroreflex mechanisms as no resetting of 
baroreflex function curves toward higher MAP was observed (54).  Although the arterial 
baroreflex and the CCR are mediated via similar medullary pathways (131), there was a 
significant difference in A2a receptor modulation of these two reflexes, powerful inhibition 
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of the CCR observed in the present study and lack of inhibition of arterial baroreflex 
reactivity observed in a previous study (54).  These differences support the hypothesis 
that adenosine receptor subtypes are differentially located in different reflex pathways at 
the level of the NTS. 
It should be stressed that in the NTS adenosine operates mostly via A2a 
receptors with a much smaller contribution of A1 receptors.  This remains in contrast to 
action of adenosine in most of the central nervous system where A1 receptor inhibitory 
action prevails (16; 91).  Microinjections of adenosine and selective A2a receptor 
agonist, CGS-21680, in to the NTS evoke similar responses, i.e. decreases in MAP 
whereas stimulation of NTS A1 adenosine receptors evokes the opposite effect to those 
evoked by adenosine and the A2a receptor agonist (8; 10).  The less potent A1 receptors 
inhibit both arterial baroreflex and CCR mechanisms in the NTS via direct inhibition of 
glutamatergic transmission in both pathways.  In contrast the dominant A2a adenosine 
receptors selectively inhibit the CCR reactivity via facilitation of GABA release which in 
turn inhibits transmission in this reflex arc. 
The A2a mediated GABA-ergic inhibition of CCR reactivity was similar across the 
regional sympathetic outputs despite both the differential regional sympathetic 
responses to CCR activation (RSNA>ASNA>LSNA) (53; 78) as well as the reciprocal 
changes in basal levels of regional sympathetic activity evoked by activation of NTS A2a 
adenosine receptors.  Therefore, the triggering of GABA-ergic negative feedback by 
NTS A2a receptors occurs via mechanisms independent of those responsible for the 
contrasting baseline shifts in regional sympathetic activity.  The inhibitory mechanisms 
seem also independent from those producing differential inhibition of regional 
sympathetic outputs by the CCR. 
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Contribution of GABAA and GABAB receptors to A2a-mediated inhibition of the 
CCR   
The present study showed that activation of adenosine A2a receptors inhibits the 
CCR responses mainly via postsynaptic GABAA receptors with a much smaller 
contribution of GABAB receptors which are located on both post and presynaptic sites in 
the NTS circuitry (55; 119; 140; 141).  A2a receptors are located mostly presynaptically 
in the NTS (24).  Therefore their activation most likely facilitates GABA release from 
synaptic terminals.  However, it does not exclude the possibility that A2a receptors may 
also activate NTS GABA-ergic neurons via a postsynaptic mechanism.  Both these 
mechanisms may facilitate the release of GABA which then acts mostly via postsynaptic 
GABAA receptors with much lesser effect on the presynaptic action of GABAB receptors.   
Both GABAA and GABAB receptors inhibit baroreflex activated neurons in the 
NTS (55; 119; 133; 140; 141).  Activation of GABAA receptors inhibits responses of NTS 
neurons activated from the aortic depressor or vagus nerves to a greater extent than 
activation of GABAB receptors (134; 140).  The increases in MAP evoked by selective 
stimulation of NTS GABAB receptors were reduced ~ 50% following sinoaortic 
denervation suggesting presynaptic location of these receptors on arterial baroreflex 
afferents (133).  Since the present study was performed on sinoaortic denervated 
animals this may partially explain why we observed the predominate role of GABAA 
receptors with much smaller contribution of GABAB receptors to A2a adenosine receptor 
mediated inhibition of the CCR. 
To our knowledge this is the first report demonstrating GABA-ergic inhibition of 
the CCR at the level of the NTS.  Previous studies confirmed NTS GABA-ergic inhibition 
only in arterial baro- and chemoreflex networks (141).  The present study showed that 
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GABAA but not GABAB receptors exert some tonic inhibitory effect on the CCR.  This is 
consistent with previous observations that blockade of GABAA receptors increases 
spontaneous activity of NTS neurons whereas blockade of GABAB receptors did not 
alter activity of these neurons (12; 56; 134).  
Other potential inhibitory mechanisms which may be triggered by NTS A2a 
receptors  
The present study confirmed our hypothesis that NTS A2a adenosine receptors 
inhibit the CCR reactivity via GABA-ergic mechanism with a dominant role of GABAA 
compared to GABAB receptors.  This effect was most likely mediated via direct 
facilitation of GABA release from nerve terminals or activation of NTS GABA-ergic 
neurons by A2a presynaptic and postsynaptic receptors, respectively.  However indirect 
facilitation of GABA release by NTS A2a adenosine receptors should be also considered.  
For example, activation of A2a receptors may disinhibit GABA release via direct A2a-D2 
interactions or via facilitation of release of vasoactive intestinal peptide as it has been 
shown in basal ganglia and hippocampal nerve terminals, respectively (29; 36; 47).   
A2a adenosine receptors may also facilitate dopamine release and dopamine in 
turn may inhibit afferent activation of NTS neurons (60; 61; 112).  It is also possible that 
A2a receptor mediated facilitation of glycine release may contribute to the inhibition of 
the CCR (6; 42; 65).  However, this concept is less likely, because glycinergic NTS 
neurons were found in the lateral portions of the NTS which are areas not involved in 
integration of the CCR (11).   In addition, inhibitory potentials triggered in NTS neurons 
via afferent vagal stimulation were reduced by blockade of GABA but not glycine (134).  
It should be stressed, that A2a receptor-mediated inhibition of the CCR was 
virtually abolished by blockade of GABAA receptors and significantly attenuated by 
87 
 
blockade of GABAB receptors (Figure 16 and 17).  These data strongly suggest that the 
majority of inhibition of the CCR exerted by A2a adenosine receptors is mediated via 
GABA-ergic mechanism with smaller if any contribution of other inhibitory mechanisms 
which may be triggered in the NTS by activation of A2a adenosine receptors.  
Nevertheless, all the above potential possibilities should be considered in future studies 
addressing mechanisms of inhibitory action of A2a receptors in the NTS.  
Limitations of the method  
 The limitations 
concerning the method of 
evoking the CCR 
responses and whole nerve 
recordings were discussed 
in detail in our previous 
study (53).  Here we focus 
on the limitations of 
blockade of GABA receptor 
subtypes in the NTS.  
Usually blockade of 
GABAA receptors in 
medullary nuclei is 
achieved with up to 500 pmol/ 100 nl of bicuculline (79; 82; 89).  However this level of 
complete blockade of GABAA receptors in the NTS was not possible as removal of 
negative feedback control of all autonomic reflexes integrated in the NTS results in 
great instability of hemodynamic and sympathetic variables as  observed  during  
Figure 20. An example of effect of bilateral microinjections of high dose of 
Bicuculline (100 pmol/100 nl) into the right (R) and left (L) sides of the NTS on  
baseline values of mean arterial pressure (MAP), heart rate (HR), adrenal and 
lumbar sympathetic nerve activity recorded in one animal.  Approximately 10 
sec following the microinjections all baselines become markedly unstable.  
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preliminary  studies.  Figure 20 shows the effect of bilateral microinjection of 100 pmol 
of bicuculline in 100 nl of ACF on baseline levels of hemodynamic variables and 
regional sympathetic nerve activity.  High amplitude flickering of baseline values 
occurred in all variables.  Therefore in preliminary studies we assessed the optimal 
dose of the antagonist which will effectively inhibit NTS GABA-ergic mechanisms, yet 
will not destabilize the resting baseline values so that the reflex responses may be 
analyzed and compared with control conditions.  We achieved this effect with 
microinjections of 10 pmol of bicuculline in 100 nl volume.  We also attempted to 
combine GABAA and GABAB receptors blockade; however, removal of virtually all 
GABA-ergic tone in the NTS yielded in marked decreases in baseline levels of MAP, HR 
and sympathetic nerve activity which made the comparisons with control conditions very 
difficult and perhaps unreliable.  Therefore, we abandoned the double blockade.  
Perspectives 
The present study revealed the presence of GABA-ergic inhibition of the CCR 
which may be triggered by stimulation of NTS A2a adenosine receptors.  NTS A1 
adenosine receptors exert similarly powerful inhibition of the CCR (53).  Although A1 
adenosine receptors inhibit also arterial baroreflex pathway at the level of the NTS, A2a 
receptors selectively inhibit the CCR but not arterial baroreflex pathway (54; 102).  
Taken together these data show that adenosine operating in the NTS powerfully inhibits 
the CCR mechanisms via synergistic action of both antagonistic receptor subtypes 
(dominant A2a and secondary A1 receptors) whereas arterial baroreflex is inhibited to 
much lesser extent as this occurs only via  A1 adenosine receptors.  Why then does 
adenosine exert such powerful inhibition of the CCR pathway compared to a much 
smaller inhibition of the arterial baroreflex pathway?  It is likely that this powerful 
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modulation of the CCR via both adenosine receptor subtypes has physiological 
implications.  The CCR (also known as the Bezold-Jarisch reflex) evokes life 
threatening decreases in MAP via marked sympatho-inhibition, peripheral vasodilation 
and severe bradycardia which may result in fainting (13; 68; 97).  This reflex is even 
implicated in mediating sudden cardiac death in young athletes (13).  The powerful 
reflex decreases in MAP may lead to brainstem hypoxia and release of adenosine.  
Therefore adenosine may work as a negative feedback regulator of this particular 
sympathoinhibitory  reflex  as  shown in Figure 21.   During cardiac ischemia moderate  
 
activation of the CCR, buffered by simultaneous activation of sympathetic afferents, 
may be helpful as it would reduce afterload and decrease oxygen demand in the 
Figure 21. Potential fine tuning of the CCR by adenosine released into the NTS. Diagram shows direct and 
indirect adenosinergic inhibition of cardiopulmonary chemoreflex (CCR) via A1 (inhibitory) and A2a (facilitatory) 
receptors under conditions when activation of the CCR is becoming detrimental for the organism (BAD) and may 
lead to release of adenosine into the NTS. A1 adenosine receptors directly inhibit glutamatergic transmission in the 
CCR pathway whereas A2a receptors facilitate the release of GABA which in turn inhibits transmission in the reflex 
pathway. Note that moderate activation of the CCR is cardioprotective (GOOD) and does not lead to release of 
adenosine into the NTS. 
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hypoxic heart.  However, powerful activation of this reflex may be detrimental as 
amplification of the hypotension might lead to death.  During this severe hypotension 
adenosine may be released into the NTS and powerfully inhibit the CCR mechanism via 
both receptor subtypes.  This occurs via different mechanisms: direct inhibition of 
glutamatergic neurotransmission in the CCR pathway and facilitation of GABA release 
via A1 and A2a receptors, 
respectively.  This 
synergistic inhibitory action 
of both adenosine receptor 
subtypes may act as a 
strong negative feedback 
regulator for the CCR 
preventing life threatening 
effects of powerful 
activation of this reflex.  
This and our 
previous studies (53; 54; 
78; 102) implicate specific, 
differential  sites of action 
for adenosine receptor 
subtypes in sympathoinhibitory cardiovascular reflexes integrated in the NTS (Figure 
22).  Adenosine operating via the less powerful A1 receptors in the NTS inhibits both the 
arterial baroreflex and the CCR via inhibition of glutamate release.  However the 
dominant A2a receptors selectively inhibit the CCR via presynaptic facilitation of GABA 
Figure 22. Hypothetical sites of action of A1 and A2a adenosine receptor 
subtypes on NTS neurons/terminals mediating the CCR and arterial 
baroreflex within NTS network. RVLM and CVLM are rostral and caudal 
ventrolateral medulla, respectively.  Dotted arrows represent nerve 
terminals descending to the NTS from higher structures via which 
adenosine may modulate baseline levels of hemodynamic and neural 
variables independently of modulation of the reflex mechanisms.  A1 
adenosine receptors (filled arrows) may directly inhibit the CCR and arterial 
baroreflex pathways while A2a receptors (open arrows) may inhibit the CCR 
selectively by activation of GABA-ergic neurons and/or terminals linked to 
the CCR pathway in the NTS.  Note that the CCR pathway is inhibited by 
both adenosine receptor subtypes (A2a receptors which dominate in the 
NTS and A1 receptors which are less potent in the NTS) whereas the 
arterial baroreflex pathway is inhibited to much lesser extent via the weaker 
A1 adenosine receptors only.   
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release or postsynaptic activation of NTS GABA-ergic neurons.  Specific location of A1 
and A2a receptors in NTS circuitry require further investigation.  Our preliminary data are 
consistent with the implications from our functional studies presented in Figure 22 (76; 
77). 
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ABSTRACT 
MECHANISMS MEDIATING MODULATION OF CARDIOPULMONARY 
CHEMOREFLEX CONTROL OF REGIONAL SYMPATHETIC ACTIVITY BY 
ADENOSINE A1 and A2a RECEPTORS LOCATED IN THE NTS 
 
by 
ZELJKA MINIC 
August 2013 
Advisor: Dr. Tadeusz J. Scislo 
Major: Physiology 
Degree: Doctor of Philosophy 
Adenosine is an important neuromodulator of cardiovascular control at the level 
of the nucleus of the solitary tract (NTS) where cardiovascular and other autonomic 
reflexes are primarily integrated. Levels of adenosine increase in the NTS during life 
threatening hypotension, ischemia and hypoxia.  Adenosine may modulate 
cardiovascular reflexes to correct hemodynamic imbalance, acting via A1 and A2a 
receptors which inhibit and facilitate neurotransmitter release, respectively.  Previous 
studies from our laboratory showed that NTS A1 adenosine receptors inhibit the arterial 
baroreflex whereas A2a receptors do not reset baroreflex control of regional sympathetic 
outputs, although stimulation of these receptors decreases renal (RSNA) increases 
preganglionic adrenal (pre-ASNA) and does not alter lumbar (LSNA) sympathetic nerve 
activity.  Cardiopulmonary chemoreflex (CCR), also known as Bezold-Jarisch reflex, 
triggered by various chemicals inhaled or released during myocardial ischemia, may 
have beneficial effects when it decreases afterload and heart rate thus decreasing 
oxygen demand.  However, strong activation of the CCR may cause severe bradycardia 
and hypotension leading to hypoperfusion of vital organs, fainting and even death.  
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During this severe reflex hypotension adenosine may be released into NTS. Then 
adenosine may inhibit the reflex to regain hemodynamic balance.  A1 adenosine 
receptors likely inhibit glutamatergic transmission in the CCR pathway as they inhibit the 
arterial baroreflex mediated via similar medullary pathways and transmitters.  
Interestingly, preliminary data showed that NTS A2a facilitatory receptors also inhibit the 
CCR.  Therefore I hypothesized that adenosine operating via both receptor subtypes 
may act as negative feedback regulator for CCR control of regional sympathetic outputs 
acting via two different mechanisms: A1 receptors mediated direct inhibition and A2a 
receptor mediated facilitation of release of an inhibitory neurotransmitter (most likely 
GABA) which in turn inhibits the CCR pathway.   Since both NTS A1 and A2a adenosine 
receptors exert differential effects on regional sympathetic outputs I anticipated that the 
inhibition of CCR control of regional sympathetic outputs will be also regionally specific.  
In urethane-chloralose-anesthetized rats I compared regional reflex 
sympathoinhibition evoked by activation of cardiopulmonary receptors with intra-atrial 
injections of phenylbiguanide (1-8 g/kg) before and after stimulation of NTS A1 and A2a 
adenosine receptors via microinjections into the NTS of N6cyclopentyl adenosine (0.33-
330 pmol/50 nl) and CGS 21680 (0.2-20 pmol/50 nl), respectively. The comparisons 
were made also following nonselective blockade of A1 and A2a receptors ((8-(p-
sulfofenyl) theophyline, 1 nmol/100 nl)) and selective blockade of A2a receptors (ZM-
2143285, 40 pmol/ 100 nl) and following respective volume controls.  Gradual 
stimulation of both A1 and A2a adenosine receptors located in the NTS caused similar 
dose dependent inhibition of hemodynamic and regional sympathetic responses. The 
inhibition was independent of differential effects of adenosine receptor subtypes in 
regional sympathetic activity suggesting that these two effects are mediated via different 
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mechanisms in the NTS.  Blockade of adenosine receptor subtypes did not affect the 
CCR showing that under normal conditions adenosine levels are too low to affect the 
reflex. Blockade of GABAA receptors in the NTS (Bicuculline, 10 pmol/100 nl) removed 
A2a receptor mediated inhibition of the reflex whereas blockade of GABAB receptors 
(SCH-50911, 1 nmol/100 nl) attenuated the A2a receptor mediated inhibition to a lesser 
extent. I found also that GABA operating via GABAA but not GABAB receptors exerts 
small, but significant tonic inhibition of the CCR. In addition, simultaneous recordings 
from the three sympathetic outputs showed that CCR differentially inhibits regional 
sympathetic outputs (RSNA>pre-ASNA>LSNA); this observation clarified inconsistent 
reports on CCR control of these sympathetic outputs.  
I conclude that adenosine may act as a negative feedback regulator of the CCR 
control of neural and hemodynamic variables. NTS A1 receptors directly inhibit 
glutamatergic transmission in the reflex pathway, whereas A2a receptors facilitate 
release of GABA which inhibits the CCR pathway mostly via GABAA receptors. 
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